hydrate - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	hydrate	go back to main search page
Accession:	CHEBI:35505	browse the term
Definition:	An addition compound that contains water in weak chemical combination with another compound.
Synonyms:	related_synonym:	Hydrat; hidrato; hidratos; hydrates

show annotations for term's descendants Sort by:
Rat (704) Mouse (717) Human (720) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (720)

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

aldo-keto reductase family 1 member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-X-C motif chemokine ligand 8

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of CXCL8 protein

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260

G

cytochrome P450 family 27 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898

G

fibroblast growth factor 19

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

glucose-6-phosphate dehydrogenase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572

G

glutamate-cysteine ligase catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

glutamic-oxaloacetic transaminase 1

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

glutamic--pyruvic transaminase

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

glutathione-disulfide reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

malic enzyme 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

nuclear receptor subfamily 0 group B member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

solute carrier family 10 member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 51 member A

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178

G

solute carrier family 7 member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

carbidopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]

PMID:34560070 PMID:35202708

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

PMID:34560070 PMID:35202708

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]

PMID:34560070 PMID:35202708

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]

PMID:34560070 PMID:35202708

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Carbidopa

NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,371...19,969,975

G

dopa decarboxylase

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA]
Carbidopa binds to and results in decreased activity of DDC protein

PMID:35151785 PMID:35202708

NCBI chr 7:50,458,442...50,565,405
Ensembl chr 7:50,458,436...50,565,405

G

dynamin 1 like

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]

NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650

G

fission, mitochondrial 1

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]

NCBI chr 7:101,239,472...101,245,081
Ensembl chr 7:101,239,458...101,252,316

G

glutamic--pyruvic transaminase

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

interleukin 1 beta

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

monoamine oxidase A

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]

PMID:34560070 PMID:35202708

NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817

G

mitofusin 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]

NCBI chr 3:179,347,709...179,394,936
Ensembl chr 3:179,347,709...179,394,936

G

mitochondrially encoded ATP synthase membrane subunit 6

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]

NCBI chr MT:8,527...9,207
Ensembl chr MT:8,527...9,207

G

mitochondrially encoded cytochrome b

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]

NCBI chr MT:14,747...15,887
Ensembl chr MT:14,747...15,887

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]

NCBI chr MT:3,307...4,262
Ensembl chr MT:3,307...4,262

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

signal transducer and activator of transcription 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

tumor necrosis factor

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tryptophan hydroxylase 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]

NCBI chr11:18,017,555...18,046,269
Ensembl chr11:18,017,555...18,046,269

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4 (PEL blood group)

increases transport

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

dihydrofolate reductase

decreases activity

Ceftazidime results in decreased activity of DHFR protein

NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983

G

heat shock transcription factor 1

decreases activity

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720

G

interleukin 10

multiple interactions

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

cilazapril monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects response to substance

ACE gene polymorphism affects the susceptibility to Cilazapril

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

adiponectin, C1Q and collagen domain containing

increases expression

Cilazapril results in increased expression of ADIPOQ protein

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

angiotensin II receptor type 1

multiple interactions

[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]

NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008

G

angiotensin II receptor type 2

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]

NCBI chr X:116,170,744...116,174,974
Ensembl chr X:116,170,744...116,174,974

G

fibroblast growth factor 2

decreases expression

Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

natriuretic peptide A

multiple interactions
affects secretion

[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein
Cilazapril affects the secretion of NPPA protein

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

renin

increases activity

Cilazapril results in increased activity of REN protein

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

solute carrier family 15 member 1

multiple interactions

Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672

G

solute carrier family 15 member 2

multiple interactions

Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr 3:121,894,401...121,944,188
Ensembl chr 3:121,894,401...121,944,188

G

transforming growth factor beta 1

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Antimony Potassium Tartrate results in decreased expression of A2M mRNA

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

affects response to substance
decreases response to substance
increases secretion
multiple interactions

ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in increased secretion of Antimony Potassium Tartrate
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]

PMID:10025956 PMID:10348353 PMID:11278867 PMID:12018890 PMID:12731862

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA

PMID:11408547 PMID:32076005

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC3 mRNA

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

acid phosphatase 2, lysosomal

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA

NCBI chr11:47,239,302...47,248,814
Ensembl chr11:47,239,302...47,248,906

G

acyl-CoA synthetase long chain family member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACSL1 mRNA

NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818

G

adrenomedullin

increases expression

Antimony Potassium Tartrate results in increased expression of ADM mRNA

NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397

G

aldo-keto reductase family 1 member B

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of AKR1B1 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B1 mRNA

PMID:17547211 PMID:28713220

NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA

PMID:28713220 PMID:32076005

NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412

G

aldo-keto reductase family 1 member C2

increases expression

Antimony Potassium Tartrate results in increased expression of AKR1C2 protein

NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031

G

aldo-keto reductase family 1 member C3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA

PMID:28713220 PMID:32076005

NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686

G

aldehyde dehydrogenase 3 family member A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ALDH3A2 mRNA

NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760

G

aldehyde dehydrogenase 3 family member B2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr11:67,662,155...67,681,252
Ensembl chr11:67,662,155...67,681,224

G

aldehyde dehydrogenase 6 family member A1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ALDH6A1 mRNA

NCBI chr14:74,056,847...74,084,453
Ensembl chr14:74,056,847...74,084,492

G

aldolase, fructose-bisphosphate A

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOA mRNA

NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457

G

aldolase, fructose-bisphosphate C

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOC mRNA

NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948

G

androgen receptor

increases phosphorylation

Antimony Potassium Tartrate results in increased phosphorylation of AR protein

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ATPase plasma membrane Ca2+ transporting 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ATP2B1 mRNA

NCBI chr12:89,588,049...89,709,366
Ensembl chr12:89,588,049...89,709,366

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

Antimony Potassium Tartrate results in decreased expression of AZGP1 mRNA

NCBI chr 7:99,966,730...99,976,031
Ensembl chr 7:99,966,720...99,976,042

G

BARX homeobox 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BARX2 mRNA

NCBI chr11:129,375,233...129,452,279
Ensembl chr11:129,375,848...129,452,279

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of BAX protein

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein
666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

bone morphogenetic protein 6

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728

G

basic transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTF3 mRNA

NCBI chr 5:73,498,442...73,505,667
Ensembl chr 5:73,498,408...73,505,667

G

BTG anti-proliferation factor 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTG2 mRNA

NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602

G

calmodulin like 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of CALML5 mRNA

NCBI chr10:5,498,697...5,499,570
Ensembl chr10:5,498,697...5,499,570

G

calreticulin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CALR mRNA

NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489

G

caspase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased cleavage of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

carbonyl reductase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CBR1 mRNA

NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166

G

cyclin B2

increases expression

Antimony Potassium Tartrate results in increased expression of CCNB2 mRNA

NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045

G

cyclin D1

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cyclin dependent kinase inhibitor 1A

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN1A mRNA

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

cyclin dependent kinase inhibitor 2B

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CDKN2B mRNA

NCBI chr 9:22,002,903...22,009,313
Ensembl chr 9:22,002,903...22,009,305

G

cyclin dependent kinase inhibitor 3

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN3 mRNA

NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218

G

CCAAT enhancer binding protein alpha

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CEBPA mRNA

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

complement factor B

decreases expression

Antimony Potassium Tartrate results in decreased expression of CFB mRNA

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

CDC28 protein kinase regulatory subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of CKS2 mRNA

NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703

G

calmegin

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLGN mRNA

NCBI chr 4:140,388,453...140,427,648
Ensembl chr 4:140,388,453...140,427,661

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLPTM1 mRNA

NCBI chr19:44,954,585...44,993,341
Ensembl chr19:44,954,585...44,993,341

G

CCHC-type zinc finger nucleic acid binding protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CNBP mRNA

NCBI chr 3:129,167,827...129,183,896
Ensembl chr 3:129,167,827...129,183,922

G

cAMP responsive element binding protein 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]

PMID:32920012 PMID:34571074

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

cystatin SA

decreases expression

Antimony Potassium Tartrate results in decreased expression of CST2 mRNA

NCBI chr20:23,823,769...23,826,729
Ensembl chr20:23,823,769...23,826,729

G

cytochrome P450 family 1 subfamily B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CYP1B1 mRNA

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

DAZ associated protein 1

increases expression

Antimony Potassium Tartrate results in increased expression of DAZAP1 mRNA

NCBI chr19:1,407,586...1,435,684
Ensembl chr19:1,407,569...1,435,687

G

decapping mRNA 1A

increases expression

Antimony Potassium Tartrate results in increased expression of DCP1A mRNA

NCBI chr 3:53,283,429...53,347,543
Ensembl chr 3:53,283,429...53,347,586

G

dehydrogenase/reductase 9

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DHRS9 mRNA

NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DNAJB1 mRNA

NCBI chr19:14,514,769...14,560,391
Ensembl chr19:14,514,769...14,560,391

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of DNAJB4 mRNA

NCBI chr 1:77,979,175...78,017,964
Ensembl chr 1:77,979,175...78,017,964

G

desmocollin 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]

PMID:28713220 PMID:32076005

NCBI chr18:31,129,236...31,162,856
Ensembl chr18:31,129,236...31,162,856

G

desmoglein 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:31,318,160...31,359,246
Ensembl chr18:31,318,160...31,359,246

G

dystonin

decreases expression

Antimony Potassium Tartrate results in decreased expression of DST protein

NCBI chr 6:56,457,996...56,954,830
Ensembl chr 6:56,457,987...56,954,830

G

dual oxidase 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA
Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr15:45,129,994...45,165,574
Ensembl chr15:45,129,933...45,165,576

G

dual oxidase maturation factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of DUOXA1 mRNA

NCBI chr15:45,117,366...45,129,879
Ensembl chr15:45,117,366...45,129,938

G

dual specificity phosphatase 1

increases expression

Antimony Potassium Tartrate results in increased expression of DUSP1 mRNA

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

dual specificity phosphatase 12

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]

NCBI chr 1:161,749,786...161,757,238
Ensembl chr 1:161,749,758...161,757,238

G

dual specificity phosphatase 2

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440

G

early growth response 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EGR3 mRNA

NCBI chr 8:22,687,659...22,693,480
Ensembl chr 8:22,687,659...22,693,480

G

ETS homologous factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EHF mRNA

NCBI chr11:34,621,093...34,663,288
Ensembl chr11:34,621,093...34,663,288

G

E74 like ETS transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ELF3 mRNA

NCBI chr 1:202,010,587...202,017,183
Ensembl chr 1:202,007,945...202,017,183

G

EPH receptor A1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA1 protein

NCBI chr 7:143,391,129...143,408,856
Ensembl chr 7:143,390,289...143,408,856

G

EPH receptor A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA2 protein

NCBI chr 1:16,124,337...16,156,069
Ensembl chr 1:16,124,337...16,156,069

G

epoxide hydrolase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of EPHX1 mRNA

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

coagulation factor V

decreases expression

Antimony Potassium Tartrate results in decreased expression of F5 mRNA

NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588

G

fatty acid binding protein 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of FABP5 mRNA

NCBI chr 8:81,280,536...81,284,775
Ensembl chr 8:81,280,536...81,284,777

G

farnesyl-diphosphate farnesyltransferase 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDFT1 mRNA

NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395

G

farnesyl diphosphate synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDPS mRNA

NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666

G

fibroblast growth factor receptor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FGFR3 mRNA

NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872

G

filaggrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of FLG mRNA
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

PMID:28713220 PMID:32076005

NCBI chr 1:152,302,165...152,325,239
Ensembl chr 1:152,302,165...152,325,239

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOS mRNA

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Antimony Potassium Tartrate results in increased expression of FOSL1 mRNA

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

forkhead box Q1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOXQ1 mRNA

NCBI chr 6:1,312,098...1,314,758
Ensembl chr 6:1,312,098...1,314,758

G

ferritin heavy chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA

PMID:28713220 PMID:32076005

NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634

G

ferritin light chain

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTL mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA

PMID:28713220 PMID:32076005

NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879

G

glucose-6-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of G6PD mRNA; Antimony Potassium Tartrate results in increased expression of G6PD protein

NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of GAPDH mRNA

NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374

G

glutamate-cysteine ligase catalytic subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA

PMID:28713220 PMID:32076005

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLM mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Antimony Potassium Tartrate results in increased expression of GCNT3 mRNA

NCBI chr15:59,549,039...59,622,723
Ensembl chr15:59,594,875...59,640,239

G

glial fibrillary acidic protein

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]

NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937

G

gamma-glutamyltransferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GGT1 mRNA

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

growth hormone inducible transmembrane protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of GHITM mRNA

NCBI chr10:84,139,509...84,153,568
Ensembl chr10:84,139,482...84,154,841

G

galactosidase alpha

increases expression

Antimony Potassium Tartrate results in increased expression of GLA mRNA

NCBI chr X:101,397,803...101,407,925
Ensembl chr X:101,393,273...101,408,012

G

glutaredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GLRX mRNA

NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726

G

glutathione peroxidase 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

grainyhead like transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of GRHL1 mRNA

NCBI chr 2:9,951,693...10,002,277
Ensembl chr 2:9,951,693...10,002,277

G

glutathione S-transferase omega 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GSTO1 mRNA

NCBI chr10:104,254,173...104,267,455
Ensembl chr10:104,235,356...104,267,459

G

GTP binding protein 6 (putative)

increases expression

Antimony Potassium Tartrate results in increased expression of GTPBP6 mRNA

NCBI chr  X:304,759...318,796
NCBI chr  Y:304,759...318,796
Ensembl chr  Y:304,529...318,796
Ensembl chr  X:304,529...318,796

G

H4 clustered histone 3

increases expression

Antimony Potassium Tartrate results in increased expression of H4C3 mRNA

NCBI chr 6:26,103,933...26,104,337
Ensembl chr 6:26,103,933...26,104,337

G

helicase like transcription factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HLTF mRNA

NCBI chr 3:149,030,063...149,086,533
Ensembl chr 3:149,030,127...149,086,554

G

high mobility group AT-hook 1

increases expression

Antimony Potassium Tartrate results in increased expression of HMGA1 mRNA

NCBI chr 6:34,236,873...34,246,231
Ensembl chr 6:34,236,873...34,246,231

G

heme oxygenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

HOP homeobox

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of HOPX mRNA

NCBI chr 4:56,647,998...56,681,706
Ensembl chr 4:56,647,989...56,681,877

G

hydroxysteroid 17-beta dehydrogenase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B2 mRNA

NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534

G

hydroxysteroid 17-beta dehydrogenase 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B7 mRNA

NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA1A mRNA

NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA8 mRNA

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

heat shock protein family B (small) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPB8 mRNA

NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855

G

HIV-1 Tat interactive protein 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HTATIP2 mRNA

NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782

G

inhibitor of DNA binding 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ID1 mRNA

NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515

G

immediate early response 2

increases expression

Antimony Potassium Tartrate results in increased expression of IER2 mRNA

NCBI chr19:13,150,411...13,154,911
Ensembl chr19:13,150,411...13,154,911

G

interferon related developmental regulator 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of IFRD1 mRNA

NCBI chr 7:112,423,174...112,477,203
Ensembl chr 7:112,422,887...112,481,017

G

IKAROS family zinc finger 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IKZF2 mRNA

NCBI chr 2:212,999,698...213,152,456
Ensembl chr 2:212,999,691...213,152,427

G

interleukin 1 receptor antagonist

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IL1RN mRNA

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 4

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

inhibitor of growth family member 3

increases expression

Antimony Potassium Tartrate results in increased expression of ING3 mRNA

NCBI chr 7:120,950,777...120,977,216
Ensembl chr 7:120,950,763...120,977,216

G

integrin subunit beta 3 binding protein

increases expression

Antimony Potassium Tartrate results in increased expression of ITGB3BP mRNA

NCBI chr 1:63,440,770...63,529,187
Ensembl chr 1:63,440,770...63,593,721

G

inter-alpha-trypsin inhibitor heavy chain 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of ITIH3 mRNA

NCBI chr 3:52,794,796...52,808,797
Ensembl chr 3:52,794,768...52,808,799

G

involucrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:152,908,546...152,911,886
Ensembl chr 1:152,908,546...152,911,886

G

KLF transcription factor 5

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KLF5 mRNA

NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541

G

KLF transcription factor 6

increases expression

Antimony Potassium Tartrate results in increased expression of KLF6 mRNA

NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281

G

kallikrein related peptidase 3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of KLK3 mRNA; Antimony Potassium Tartrate results in increased expression of KLK3 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

keratin 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]

NCBI chr12:52,674,736...52,680,407
Ensembl chr12:52,674,736...52,680,407

G

keratin 10

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]

PMID:28713220 PMID:32076005

NCBI chr17:40,818,117...40,822,614
Ensembl chr17:40,818,117...40,822,614

G

keratinocyte differentiation associated protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of KRTDAP mRNA

NCBI chr19:35,487,324...35,490,464
Ensembl chr19:35,487,324...35,495,558

G

lipase A, lysosomal acid type

decreases expression

Antimony Potassium Tartrate results in decreased expression of LIPA mRNA

NCBI chr10:89,213,572...89,251,775
Ensembl chr10:89,213,569...89,414,557

G

loricrin cornified envelope precursor protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of LORICRIN mRNA

NCBI chr 1:153,259,687...153,262,124
Ensembl chr 1:153,259,687...153,262,124

G

leucine rich repeats and immunoglobulin like domains 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA

NCBI chr 3:66,378,797...66,501,121
Ensembl chr 3:66,378,797...66,501,263

G

lanosterol synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of LSS mRNA

NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824

G

MAF bZIP transcription factor F

increases expression

Antimony Potassium Tartrate results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

mannosidase alpha class 1A member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MAN1A2 mRNA

NCBI chr 1:117,367,449...117,528,872
Ensembl chr 1:117,367,449...117,528,872

G

monoamine oxidase A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of MAOA mRNA

NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817

G

mitogen-activated protein kinase kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MAP2K1 mRNA

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

minichromosome maintenance complex component 2

increases expression

Antimony Potassium Tartrate results in increased expression of MCM2 mRNA

NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,410...127,622,436

G

malic enzyme 1

increases expression

Antimony Potassium Tartrate results in increased expression of ME1 mRNA

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

decreases expression

Antimony Potassium Tartrate results in decreased expression of MGAT2 mRNA

NCBI chr14:49,620,799...49,623,481
Ensembl chr14:49,620,799...49,623,481

G

microsomal glutathione S-transferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MGST1 mRNA

NCBI chr12:16,347,115...16,593,331
Ensembl chr12:16,347,142...16,609,259

G

metallothionein 1E

increases expression

Antimony Potassium Tartrate results in increased expression of MT1E mRNA

NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112

G

metallothionein 1X

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of MT1X mRNA
Antimony Potassium Tartrate results in increased expression of MT1X mRNA

PMID:17547211 PMID:28713220

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

metallothionein 2A

increases expression

Antimony Potassium Tartrate results in increased expression of MT2A mRNA

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate
MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate

NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007

G

NDRG family member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NDRG2 mRNA

NCBI chr14:21,016,763...21,070,872
Ensembl chr14:21,016,763...21,070,872

G

nuclear factor kappa B subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NFKB2 mRNA

NCBI chr10:102,394,110...102,402,529
Ensembl chr10:102,394,110...102,402,524

G

NFKB inhibitor alpha

decreases expression

Antimony Potassium Tartrate results in decreased expression of NFKBIA mRNA

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NK3 homeobox 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]

NCBI chr 8:23,678,693...23,682,938
Ensembl chr 8:23,678,697...23,682,938

G

nitric oxide synthase 2

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA

PMID:28713220 PMID:32076005

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression

Antimony Potassium Tartrate results in increased expression of NQO2 mRNA

NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,019,755

G

nuclear receptor subfamily 0 group B member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

OS9 endoplasmic reticulum lectin

decreases expression

Antimony Potassium Tartrate results in decreased expression of OS9 mRNA

NCBI chr12:57,694,132...57,721,557
Ensembl chr12:57,693,841...57,728,342

G

oncostatin M

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]

NCBI chr22:30,262,829...30,266,851
Ensembl chr22:30,262,829...30,266,851

G

PBX homeobox 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PBX1 mRNA

NCBI chr 1:164,559,184...164,886,047
Ensembl chr 1:164,555,584...164,899,296

G

proliferating cell nuclear antigen

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PCNA protein

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

protein disulfide isomerase family A member 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of PDIA4 mRNA

NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662

G

progastricsin

decreases expression

Antimony Potassium Tartrate results in decreased expression of PGC mRNA

NCBI chr 6:41,736,711...41,747,397
Ensembl chr 6:41,736,711...41,754,109

G

phosphogluconate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of PGD protein

NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511

G

phosphoglucomutase 1

increases expression

Antimony Potassium Tartrate results in increased expression of PGM1 mRNA

NCBI chr 1:63,593,411...63,660,245
Ensembl chr 1:63,593,411...63,660,245

G

phosphoglucomutase 3

increases expression

Antimony Potassium Tartrate results in increased expression of PGM3 mRNA

NCBI chr 6:83,148,705...83,193,900
Ensembl chr 6:83,147,324...83,193,936

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R1 mRNA

NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821

G

phosphoinositide-3-kinase regulatory subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R2 mRNA

NCBI chr19:18,153,163...18,170,532
Ensembl chr19:18,153,163...18,170,532

G

pirin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PIR mRNA

NCBI chr X:15,384,799...15,493,333
Ensembl chr X:15,384,799...15,493,564

G

paired like homeodomain 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PITX1 mRNA

NCBI chr 5:135,027,734...135,034,789
Ensembl chr 5:135,027,734...135,034,813

G

PML nuclear body scaffold

affects localization
multiple interactions
increases degradation

Antimony Potassium Tartrate affects the localization of PML protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased degradation of PML protein mutant form

NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827

G

RNA polymerase II subunit J2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of POLR2J2 mRNA

NCBI chr 7:102,666,046...102,671,663
Ensembl chr 7:102,665,368...102,671,663

G

peptidylprolyl isomerase H

increases expression

Antimony Potassium Tartrate results in increased expression of PPIH mRNA

NCBI chr 1:42,658,423...42,681,654
Ensembl chr 1:42,658,335...42,676,758

G

peroxiredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PRDX1 mRNA

NCBI chr 1:45,511,051...45,522,890
Ensembl chr 1:45,510,914...45,542,732

G

phosphoserine phosphatase

decreases expression

Antimony Potassium Tartrate results in decreased expression of PSPH mRNA

NCBI chr 7:56,011,064...56,051,444
Ensembl chr 7:56,011,051...56,051,604

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

Antimony Potassium Tartrate results in increased expression of PTTG1 mRNA

NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739

G

retinoic acid receptor alpha

increases degradation

Antimony Potassium Tartrate results in increased degradation of RARA protein mutant form

NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643

G

RNA binding protein, mRNA processing factor

increases expression

Antimony Potassium Tartrate results in increased expression of RBPMS mRNA

NCBI chr 8:30,384,541...30,572,256
Ensembl chr 8:30,384,511...30,572,256

G

replication factor C subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of RFC2 mRNA

NCBI chr 7:74,231,502...74,254,399
Ensembl chr 7:74,231,499...74,254,458

G

ribonuclease H2 subunit A

increases expression

Antimony Potassium Tartrate results in increased expression of RNASEH2A mRNA

NCBI chr19:12,806,584...12,813,640
Ensembl chr19:12,806,584...12,813,640

G

ribonuclease/angiogenin inhibitor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RNH1 protein

NCBI chr11:494,515...507,242
Ensembl chr11:494,512...507,300

G

repetin

decreases expression

Antimony Potassium Tartrate results in decreased expression of RPTN mRNA

NCBI chr 1:152,153,595...152,159,228
Ensembl chr 1:152,153,595...152,159,228

G

ryanodine receptor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RYR1 mRNA

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

S100 calcium binding protein A12

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A12 mRNA

NCBI chr 1:153,373,711...153,375,621
Ensembl chr 1:153,373,711...153,375,621

G

S100 calcium binding protein A2

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A2 mRNA

NCBI chr 1:153,561,108...153,565,844
Ensembl chr 1:153,561,108...153,567,890

G

S100 calcium binding protein A7

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A7 mRNA

NCBI chr 1:153,457,744...153,460,651
Ensembl chr 1:153,457,744...153,460,651

G

S100 calcium binding protein A8

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

stearoyl-CoA desaturase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SCD mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

selenophosphate synthetase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SEPHS2 mRNA

NCBI chr16:30,443,631...30,445,874
Ensembl chr16:30,443,631...30,445,874

G

serpin family B member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINB1 mRNA

NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959

G

serpin family C member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINC1 mRNA

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

G

serpin family E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

salt inducible kinase 1

increases expression

Antimony Potassium Tartrate results in increased expression of SIK1 mRNA

NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131

G

solute carrier family 2 member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SLC2A3 mRNA

NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Antimony Potassium Tartrate results in increased expression of SNRPA mRNA

NCBI chr19:40,751,203...40,765,389
Ensembl chr19:40,750,637...40,765,389

G

superoxide dismutase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SOD1 mRNA

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

small proline rich protein 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein

NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814

G

small proline rich protein 1B

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein

NCBI chr 1:153,031,203...153,032,900
Ensembl chr 1:153,031,203...153,032,900

G

small proline rich protein 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein

NCBI chr 1:153,001,749...153,003,856
Ensembl chr 1:153,001,747...153,003,856

G

squalene epoxidase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SQLE mRNA

NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283

G

sequestosome 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SQSTM1 mRNA

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

serine and arginine rich splicing factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF1 mRNA

NCBI chr17:57,989,038...58,007,246
Ensembl chr17:58,000,919...58,007,346

G

serine and arginine rich splicing factor 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF5 mRNA

NCBI chr14:69,767,142...69,772,005
Ensembl chr14:69,726,900...69,772,005

G

sulfiredoxin 1

increases expression

Antimony Potassium Tartrate results in increased expression of SRXN1 mRNA

NCBI chr20:646,615...653,200
Ensembl chr20:646,615...653,200

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of ST6GALNAC4 mRNA

NCBI chr 9:127,907,886...127,917,041
Ensembl chr 9:127,907,886...127,917,041

G

signal transducer and activator of transcription 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA

NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960

G

sulfotransferase family 1C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1C3 mRNA

NCBI chr 2:108,239,968...108,265,351
Ensembl chr 2:108,239,968...108,265,351

G

sulfotransferase family 1E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1E1 mRNA

NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145

G

sulfotransferase family 2B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT2B1 mRNA

NCBI chr19:48,552,172...48,599,427
Ensembl chr19:48,552,172...48,599,425

G

small ubiquitin like modifier 1

affects localization
multiple interactions

Antimony Potassium Tartrate affects the localization of SUMO1 protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]

NCBI chr 2:202,206,171...202,238,597
Ensembl chr 2:202,206,182...202,238,599

G

TAR DNA binding protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of TARDBP mRNA

NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,344...11,030,528

G

transglutaminase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TGM1 mRNA

NCBI chr14:24,249,114...24,263,177
Ensembl chr14:24,249,114...24,264,432

G

TNF alpha induced protein 3

increases expression

Antimony Potassium Tartrate results in increased expression of TNFAIP3 mRNA

NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314

G

TNF superfamily member 10

decreases expression

Antimony Potassium Tartrate results in decreased expression of TNFSF10 mRNA

NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475

G

transducer of ERBB2, 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of TOB1 mRNA

NCBI chr17:50,862,223...50,867,978
Ensembl chr17:50,862,223...50,867,978

G

tumor protein p63

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TP63 mRNA

NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276

G

triosephosphate isomerase 1

increases expression

Antimony Potassium Tartrate results in increased expression of TPI1 mRNA

NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948

G

TSC22 domain family member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TSC22D3 mRNA

NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342

G

tetraspanin 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of TSPAN7 mRNA

NCBI chr X:38,561,542...38,688,918
Ensembl chr X:38,561,542...38,688,920

G

tuftelin 1

increases expression

Antimony Potassium Tartrate results in increased expression of TUFT1 mRNA

NCBI chr 1:151,540,309...151,583,583
Ensembl chr 1:151,540,305...151,583,583

G

thioredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXN mRNA

NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507

G

thioredoxin reductase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

G

thymidylate synthetase

increases expression

Antimony Potassium Tartrate results in increased expression of TYMS mRNA

NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578

G

ubiquitin conjugating enzyme E2 C

increases expression

Antimony Potassium Tartrate results in increased expression of UBE2C mRNA

NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957

G

UDP glucuronosyltransferase family 1 member A6

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

ZW10 interacting kinetochore protein

increases expression

Antimony Potassium Tartrate results in increased expression of ZWINT mRNA

NCBI chr10:56,357,227...56,361,273
Ensembl chr10:56,357,227...56,361,273

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

adrenoceptor beta 1

affects expression

Enalaprilat affects the expression of ADRB1 protein

NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904

G

adrenoceptor beta 2

affects expression

Enalaprilat affects the expression of ADRB2 protein

NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623

G

angiotensinogen

decreases expression
multiple interactions

Enalaprilat results in decreased expression of AGT protein modified form
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]

PMID:16452552 PMID:21795644

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

angiotensin II receptor type 1

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008

G

BCL2 apoptosis regulator

increases expression

Enalaprilat results in increased expression of BCL2 mRNA

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

bradykinin receptor B1

multiple interactions
increases activity

bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

endothelin 1

decreases secretion

Enalaprilat results in decreased secretion of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

fibronectin 1

decreases expression
multiple interactions

Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein
Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]

PMID:14520012 PMID:21795644

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

glutamate dehydrogenase 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]

NCBI chr10:87,050,202...87,094,843
Ensembl chr10:87,050,202...87,094,843

G

glutamate metabotropic receptor 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of GRM1 mRNA]

NCBI chr 6:146,027,707...146,437,601
Ensembl chr 6:146,027,646...146,437,601

G

high mobility group box 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]

NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597

G

insulin

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

peroxisome proliferator activated receptor delta

multiple interactions

[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

renin

increases expression

Enalaprilat results in increased expression of REN mRNA

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

serpin family E member 1

decreases expression

Enalaprilat results in decreased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

solute carrier family 22 member 11

increases uptake

SLC22A11 protein results in increased uptake of Enalaprilat

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

solute carrier family 22 member 8

multiple interactions
increases uptake

verlukast inhibits the reaction [SLC22A8 protein results in increased uptake of Enalaprilat]

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier organic anion transporter family member 1B1

affects abundance

SLCO1B1 gene polymorphism affects the abundance of Enalaprilat

NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796

G

transforming growth factor beta 1

decreases expression

Enalaprilat results in decreased expression of TGFB1 mRNA; Enalaprilat results in decreased expression of TGFB1 protein

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 4

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

decreases expression

Enalaprilat results in decreased expression of TNF mRNA

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

gadodiamide hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

decreases expression

gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

gadodiamide results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

aldehyde dehydrogenase 1 family member A1

increases expression

gadodiamide results in increased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

ankyrin repeat domain 22

increases expression

gadodiamide results in increased expression of ANKRD22 mRNA

NCBI chr10:88,819,896...88,851,844
Ensembl chr10:88,819,896...88,851,844

G

apolipoprotein B mRNA editing enzyme catalytic subunit 3A

increases expression

gadodiamide results in increased expression of APOBEC3A mRNA

NCBI chr22:38,957,609...38,963,184
Ensembl chr22:38,952,741...38,963,184

G

ATM serine/threonine kinase

increases expression

gadodiamide results in increased expression of ATM mRNA

NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102

G

ATPase phospholipid transporting 8B1

increases expression

gadodiamide results in increased expression of ATP8B1 mRNA

NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315

G

C-C motif chemokine ligand 2

increases expression
increases secretion

gadodiamide results in increased expression of CCL2 mRNA
gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein
gadodiamide results in increased secretion of CCL2 protein

PMID:20938346 PMID:20959327

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 4

increases expression

gadodiamide results in increased expression of CCL4 protein

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 7

increases expression

gadodiamide results in increased expression of CCL7 protein

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

C-C motif chemokine ligand 8

increases expression
increases secretion

gadodiamide results in increased expression of CCL8 mRNA
gadodiamide results in increased secretion of CCL8 protein

NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402

G

CD1c molecule

increases expression

gadodiamide results in increased expression of CD1C mRNA

NCBI chr 1:158,289,923...158,294,774
Ensembl chr 1:158,289,923...158,294,774

G

centrosomal protein 15

increases expression

gadodiamide results in increased expression of CEP15 mRNA

NCBI chr 3:62,319,022...62,336,213
Ensembl chr 3:62,319,015...62,336,213

G

C-X-C motif chemokine ligand 10

increases expression
increases secretion

gadodiamide results in increased expression of CXCL10 mRNA
gadodiamide results in increased expression of CXCL10 protein
gadodiamide results in increased secretion of CXCL10 protein

PMID:20938346 PMID:20959327

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 11

increases secretion
increases expression

gadodiamide results in increased secretion of CXCL11 protein
gadodiamide results in increased expression of CXCL11 mRNA

NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415

G

C-X-C motif chemokine ligand 12

increases expression

gadodiamide results in increased expression of CXCL12 mRNA

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 9

increases expression

gadodiamide results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

fatty acid binding protein 4

decreases expression

gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

indoleamine 2,3-dioxygenase 1

increases expression

gadodiamide results in increased expression of IDO1 mRNA

NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790

G

interferon induced protein 44 like

increases expression

gadodiamide results in increased expression of IFI44L mRNA

NCBI chr 1:78,620,448...78,646,145
Ensembl chr 1:78,619,902...78,646,145

G

interferon induced protein with tetratricopeptide repeats 1

increases expression

gadodiamide results in increased expression of IFIT1 mRNA

NCBI chr10:89,392,623...89,406,487
Ensembl chr10:89,392,546...89,406,487

G

interferon induced protein with tetratricopeptide repeats 3

increases expression

gadodiamide results in increased expression of IFIT3 mRNA

NCBI chr10:89,327,997...89,340,968
Ensembl chr10:89,327,307...89,377,473

G

interferon gamma

increases expression

gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interleukin 13

increases expression

gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein

NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110

G

interleukin 1 alpha

increases expression

gadodiamide results in increased expression of IL1A protein

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 4

increases expression
affects expression

gadodiamide results in increased expression of IL4 protein
gadodiamide affects the expression of IL4 mRNA

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 4 induced 1

increases expression

gadodiamide results in increased expression of IL4I1 mRNA

NCBI chr19:49,889,654...49,929,504
Ensembl chr19:49,889,654...49,929,539

G

interleukin 6

affects expression
increases expression

gadodiamide affects the expression of IL6 protein
gadodiamide results in increased expression of IL6 mRNA

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

KIT ligand

increases expression

gadodiamide results in increased expression of KITLG protein

NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]
gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein

NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160

G

nitric oxide synthase 2

increases expression

gadodiamide results in increased expression of NOS2 protein

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

neurexophilin and PC-esterase domain family member 3

increases expression

gadodiamide results in increased expression of NXPE3 mRNA

NCBI chr 3:101,779,211...101,828,231
Ensembl chr 3:101,779,177...101,843,743

G

peroxisome proliferator activated receptor gamma

decreases expression

gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

RELA proto-oncogene, NF-kB subunit

increases localization

gadodiamide results in increased localization of RELA protein

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

ras homolog family member Q

increases expression

gadodiamide results in increased expression of RHOQ mRNA

NCBI chr 2:46,542,490...46,584,688
Ensembl chr 2:46,541,806...46,584,688

G

Ras like without CAAX 1

increases expression

gadodiamide results in increased expression of RIT1 mRNA

NCBI chr 1:155,897,808...155,911,349
Ensembl chr 1:155,897,808...155,911,404

G

ring finger protein 125

increases expression

gadodiamide results in increased expression of RNF125 mRNA

NCBI chr18:32,018,825...32,088,144
Ensembl chr18:32,018,825...32,073,219

G

radical S-adenosyl methionine domain containing 2

increases expression

gadodiamide results in increased expression of RSAD2 mRNA

NCBI chr 2:6,865,885...6,898,239
Ensembl chr 2:6,865,557...6,898,239

G

solute carrier family 39 member 10

increases expression

gadodiamide results in increased expression of SLC39A10 mRNA

NCBI chr 2:195,613,029...195,737,700
Ensembl chr 2:195,575,977...195,737,702

G

sialophorin

increases expression

gadodiamide results in increased expression of SPN mRNA

NCBI chr16:29,662,963...29,670,876
Ensembl chr16:29,662,979...29,670,876

G

secreted phosphoprotein 1

increases expression

gadodiamide results in increased expression of SPP1 protein

NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532

G

transforming growth factor beta 1

increases expression

gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein

PMID:19404939 PMID:20938346

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]

PMID:19561517 PMID:20938346

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

ubiquitin D

increases expression

gadodiamide results in increased expression of UBD mRNA

NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732

G

vascular endothelial growth factor A

increases expression

gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein

PMID:19404939 PMID:20938346

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

WD repeat domain 5

increases expression

gadodiamide results in increased expression of WDR5 mRNA

NCBI chr 9:134,135,199...134,159,968
Ensembl chr 9:134,135,365...134,159,968

G

X-linked inhibitor of apoptosis

increases expression

gadodiamide results in increased expression of XIAP mRNA

NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972

G

zinc finger protein 595

increases expression

gadodiamide results in increased expression of ZNF595 mRNA

NCBI chr 4:53,321...88,208
Ensembl chr 4:53,286...88,208

G

zinc finger protein 652

increases expression

gadodiamide results in increased expression of ZNF652 mRNA

NCBI chr17:49,288,117...49,362,473
Ensembl chr17:49,289,206...49,362,473

lisinopril dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

Lisinopril analog results in decreased activity of ACE protein

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

angiotensin converting enzyme 2

increases expression
multiple interactions
increases activity

Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased activity of ACE2 protein

PMID:15897343 PMID:16221218 PMID:27649628

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

acetylcholinesterase (Yt blood group)

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]

PMID:23060470 PMID:31710167

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

angiotensinogen

decreases expression
multiple interactions
affects metabolic processing
decreases secretion
increases secretion
affects response to substance
increases expression

Lisinopril results in decreased expression of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased expression of AGT mRNA

PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More...

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

BCL2 apoptosis regulator

decreases expression

Lisinopril results in decreased expression of BCL2

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

CD2 associated protein

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein]

NCBI chr 6:47,477,789...47,627,263
Ensembl chr 6:47,477,789...47,627,263

G

endothelin 1

decreases secretion

Lisinopril results in decreased secretion of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

growth hormone 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839

G

hepatitis A virus cellular receptor 1

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

major histocompatibility complex, class I, G

affects expression

Lisinopril affects the expression of HLA-G mRNA

NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125

G

heparanase

multiple interactions

[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]

NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153

G

insulin like growth factor binding protein 1

increases expression

Lisinopril results in increased expression of IGFBP1 protein

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

matrix metallopeptidase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

myeloperoxidase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

nitric oxide synthase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NPHS1 adhesion molecule, nephrin

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]

PMID:16636307 PMID:19293598

NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287

G

NPHS2 stomatin family member, podocin

multiple interactions

Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]

NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952

G

natriuretic peptide A

decreases expression

Lisinopril results in decreased expression of NPPA protein

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

renin

increases expression
multiple interactions

Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA

PMID:2550029 PMID:8915971 PMID:16221218

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

vascular endothelial growth factor A

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

mosapride citrate dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anoctamin 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]

NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530

G

5-hydroxytryptamine receptor 4

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of HTR4 mRNA]

NCBI chr 5:148,451,032...148,654,527
Ensembl chr 5:148,446,042...148,677,235

G

myosin light chain kinase

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of MYLK mRNA]

NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332

G

nitric oxide synthase 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of NOS1 protein]

NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170

G

ryanodine receptor 3

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of RYR3 mRNA]

NCBI chr15:33,310,967...33,866,102
Ensembl chr15:33,310,962...33,866,121

G

solute carrier family 22 member 2

multiple interactions

mosapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638

potassium citrate monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

neurofilament heavy chain

affects expression

Potassium Citrate affects the expression of NEFH mRNA

NCBI chr22:29,480,218...29,491,390
Ensembl chr22:29,480,218...29,491,390

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

acyl-CoA synthetase short chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr20:25,006,237...25,058,139
Ensembl chr20:25,006,230...25,058,980

G

acyl-CoA synthetase short chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily B member 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

INS-IGF2 readthrough

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr17:47,649,919...47,685,505
Ensembl chr17:47,649,476...47,685,505

G

MYD88 innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024

G

N-acetyltransferase 2

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218

G

nuclear factor of activated T cells 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr20:51,386,963...51,562,839
Ensembl chr20:51,386,957...51,562,831

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

phosphoenolpyruvate carboxykinase 1

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

superoxide dismutase 2

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

transforming growth factor beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260

G

toll like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742

sodium thiosulfate pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

myeloperoxidase

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Tacrolimus results in increased expression of A2M mRNA

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

[Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Tacrolimus results in increased expression of ABCA1 mRNA

PMID:17016853 PMID:21865292

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 1

increases response to substance
decreases activity
affects export
multiple interactions
increases export
affects response to substance

ABCB1 gene SNP results in increased susceptibility to Tacrolimus
Tacrolimus results in decreased activity of ABCB1 protein
ABCB1 protein affects the export of Tacrolimus
[Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]
ABCB1 protein affects the susceptibility to Tacrolimus

PMID:1381629 PMID:11920757 PMID:12352921 PMID:15919446 PMID:15964336 More...

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily B member 11

decreases activity

Tacrolimus results in decreased activity of ABCB11 protein

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

acetyl-CoA acyltransferase 1

decreases expression

Tacrolimus results in decreased expression of ACAA1B mRNA

NCBI chr 3:38,122,715...38,137,127
Ensembl chr 3:38,103,129...38,137,242

G

acyl-CoA dehydrogenase long chain

decreases expression

Tacrolimus results in decreased expression of ACADL mRNA

NCBI chr 2:210,187,923...210,225,447
Ensembl chr 2:210,187,126...210,225,447

G

angiotensin converting enzyme 2

decreases expression

Tacrolimus results in decreased expression of ACE2 mRNA

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

acid phosphatase 5, tartrate resistant

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]

NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993

G

actin alpha 2, smooth muscle

increases expression

Tacrolimus results in increased expression of ACTA2 protein

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

activin A receptor type 1B

multiple interactions

[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]

NCBI chr12:51,951,699...51,997,078
Ensembl chr12:51,951,699...51,997,078

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

increases expression

Tacrolimus results in increased expression of ADAMTS1 mRNA

NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

increases expression

Tacrolimus results in increased expression of ADAMTS2 mRNA

NCBI chr 5:179,110,853...179,345,461
Ensembl chr 5:179,110,853...179,345,461

G

adenylate cyclase 9

multiple interactions

Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]]

NCBI chr16:3,953,387...4,116,442
Ensembl chr16:3,953,387...4,116,442

G

adrenoceptor alpha 1D

increases expression

Tacrolimus results in increased expression of ADRA1D mRNA

NCBI chr20:4,220,630...4,249,287
Ensembl chr20:4,220,630...4,249,287

G

allograft inflammatory factor 1

increases expression

Tacrolimus results in increased expression of AIF1 mRNA

NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021

G

aldehyde dehydrogenase 1 family member A1

decreases expression

Tacrolimus results in decreased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

aldehyde dehydrogenase 2 family member

decreases expression

Tacrolimus results in decreased expression of ALDH2 mRNA

NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532

G

aldehyde dehydrogenase 9 family member A1

decreases expression

Tacrolimus results in decreased expression of ALDH9A1 mRNA

NCBI chr 1:165,662,216...165,698,562
Ensembl chr 1:165,662,216...165,698,562

G

ALG3 alpha-1,3- mannosyltransferase

decreases expression

Tacrolimus results in decreased expression of ALG3 mRNA

NCBI chr 3:184,242,301...184,249,525
Ensembl chr 3:184,242,301...184,249,548

G

angiopoietin like 6

increases expression

Tacrolimus results in increased expression of ANGPTL6 mRNA

NCBI chr19:10,092,338...10,106,190
Ensembl chr19:10,092,338...10,102,678

G

ankyrin repeat domain 1

increases expression

Tacrolimus results in increased expression of ANKRD1 mRNA

NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087

G

ankyrin repeat domain 34A

decreases expression

Tacrolimus results in decreased expression of ANKRD34A mRNA

NCBI chr 1:145,959,441...145,964,575
Ensembl chr 1:145,959,441...145,964,575

G

anosmin 1

increases expression

Tacrolimus results in increased expression of WFDC17 mRNA

NCBI chr X:8,528,874...8,732,137
Ensembl chr X:8,528,874...8,732,137

G

alanyl aminopeptidase, membrane

increases secretion

Tacrolimus results in increased secretion of ANPEP protein

NCBI chr15:89,784,895...89,814,852
Ensembl chr15:89,784,895...89,815,401

G

annexin A1

increases expression

Tacrolimus results in increased expression of ANXA1

NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393

G

amine oxidase copper containing 1

increases expression

Tacrolimus results in increased expression of AOC1 mRNA

NCBI chr 7:150,852,120...150,861,504
Ensembl chr 7:150,824,627...150,861,504

G

amphiregulin

increases expression

Tacrolimus results in increased expression of AREG mRNA

NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005

G

ADP ribosylation factor related protein 1

increases expression

Tacrolimus results in increased expression of ARFRP1 mRNA

NCBI chr20:63,698,647...63,707,976
Ensembl chr20:63,698,642...63,708,025

G

Rho GTPase activating protein 45

increases expression

Tacrolimus results in increased expression of ARHGAP45 mRNA

NCBI chr19:1,065,959...1,086,628
Ensembl chr19:1,065,923...1,086,628

G

Rho guanine nucleotide exchange factor 11

increases expression

Tacrolimus results in increased expression of ARHGEF11 mRNA

NCBI chr 1:156,934,840...157,046,903
Ensembl chr 1:156,934,840...157,045,742

G

actin related protein 2/3 complex subunit 5

increases expression

Tacrolimus results in increased expression of ARPC5 mRNA

NCBI chr 1:183,620,846...183,635,783
Ensembl chr 1:183,620,846...183,635,783

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

Tacrolimus results in increased expression of ARV1 mRNA

NCBI chr 1:230,979,094...231,000,733
Ensembl chr 1:230,978,981...231,000,733

G

ASXL transcriptional regulator 3

decreases expression

Tacrolimus results in decreased expression of ASXL3 mRNA

NCBI chr18:33,578,219...33,751,195
Ensembl chr18:33,578,219...33,751,195

G

activating transcription factor 3

increases expression

Tacrolimus results in increased expression of ATF3 mRNA

NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777

G

activating transcription factor 4

increases expression

Tacrolimus results in increased expression of ATF4 mRNA

NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683

G

activating transcription factor 6

increases expression

Tacrolimus results in increased expression of ATF6 mRNA

NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574

G

ATPase Na+/K+ transporting subunit beta 1

decreases expression

Tacrolimus results in decreased expression of ATP1B1 mRNA

NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992

G

ATPase Na+/K+ transporting subunit beta 3

decreases expression

Tacrolimus results in decreased expression of ATP1B3 mRNA

NCBI chr 3:141,876,643...141,926,549
Ensembl chr 3:141,876,124...141,926,549

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Tacrolimus results in increased expression of ATP2A2 mRNA

NCBI chr12:110,280,616...110,351,093
Ensembl chr12:110,280,756...110,351,093

G

beta-2-microglobulin

increases expression

Tacrolimus results in increased expression of B2M mRNA

NCBI chr15:44,711,517...44,718,145
Ensembl chr15:44,711,358...44,718,851

G

BCL2 associated agonist of cell death

multiple interactions

Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]

PMID:15036616 PMID:15280438

NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704

G

basic leucine zipper ATF-like transcription factor 3

increases expression

Tacrolimus results in increased expression of BATF3 mRNA

NCBI chr 1:212,686,417...212,699,840
Ensembl chr 1:212,686,417...212,699,840

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]
Tacrolimus results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein

PMID:10205001 PMID:15571979 PMID:27606422 PMID:35033536

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
decreases expression
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]
Tacrolimus results in decreased expression of BCL2 protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein
Tacrolimus results in increased expression of BCL2 protein

PMID:10205001 PMID:15571979 PMID:27606422

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 1

multiple interactions

Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein]

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989

G

BCL3 transcription coactivator

increases expression

Tacrolimus results in increased expression of BCL3 mRNA

NCBI chr19:44,747,705...44,760,044
Ensembl chr19:44,747,705...44,760,044

G

brain derived neurotrophic factor

multiple interactions

Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]; Tacrolimus promotes the reaction [U 0126 inhibits the reaction [decamethrin results in increased expression of BDNF exon]]; U 0126 promotes the reaction [Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]]

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

baculoviral IAP repeat containing 3

increases expression

Tacrolimus results in increased expression of BIRC3 mRNA

NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403

G

baculoviral IAP repeat containing 5

decreases expression

Tacrolimus results in decreased expression of BIRC5 mRNA

NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636

G

bone morphogenetic protein 7

multiple interactions
decreases expression

Ramipril inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]; valsartan inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]

NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641

G

BTG anti-proliferation factor 2

increases expression

Tacrolimus results in increased expression of BTG2 mRNA

NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602

G

butyrophilin like 9

decreases expression

Tacrolimus results in decreased expression of BTNL9 mRNA

NCBI chr 5:181,040,266...181,061,521
Ensembl chr 5:181,040,225...181,061,521

G

complement C1q A chain

increases expression

Tacrolimus results in increased expression of C1QA mRNA

NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678

G

complement C1q B chain

increases expression

Tacrolimus results in increased expression of C1QB mRNA

NCBI chr 1:22,653,236...22,661,637
Ensembl chr 1:22,652,762...22,661,637

G

complement C1q C chain

increases expression

Tacrolimus results in increased expression of C1QC mRNA

NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110

G

complement C2

increases expression

Tacrolimus results in increased expression of C2 mRNA

NCBI chr 6:31,897,783...31,945,672
Ensembl chr 6:31,897,785...31,945,673

G

complement C3

increases expression

Tacrolimus results in increased expression of C3 mRNA

PMID:21865292 PMID:29362864

NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562

G

complement C4B (Chido/Rodgers blood group)

increases expression

Tacrolimus results in increased expression of C4B mRNA

NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418

G

calbindin 1

decreases expression

Tacrolimus results in decreased expression of CALB1 mRNA; Tacrolimus results in decreased expression of CALB1 protein

PMID:14978156 PMID:21865292

NCBI chr 8:90,058,608...90,082,879
Ensembl chr 8:90,058,608...90,095,475

G

calcitonin receptor

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]

NCBI chr 7:93,424,486...93,574,724
Ensembl chr 7:93,424,486...93,574,730

G

calreticulin

increases expression

Tacrolimus results in increased expression of CALR mRNA

NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489

G

calcium/calmodulin dependent protein kinase ID

increases expression

Tacrolimus results in increased expression of CAMK1D mRNA

NCBI chr10:12,349,547...12,835,545
Ensembl chr10:12,349,547...12,835,545

G

capping actin protein, gelsolin like

increases expression

Tacrolimus results in increased expression of CAPG mRNA

NCBI chr 2:85,391,602...85,419,540
Ensembl chr 2:85,394,753...85,418,432

G

caspase 3

multiple interactions
increases cleavage
increases activity

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
Tacrolimus results in increased cleavage of CASP3 protein
Tacrolimus results in increased activity of CASP3 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]

PMID:10205001 PMID:12642403 PMID:12871656 PMID:12892836 PMID:15207740 More...

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
Tacrolimus results in increased expression of CASP8 protein

PMID:15548389 PMID:27606422

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]
Tacrolimus results in increased expression of CASP9 protein

PMID:15548389 PMID:27606422

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catalase

increases expression
decreases response to substance

Tacrolimus results in increased expression of CAT protein
CAT protein results in decreased susceptibility to Tacrolimus

PMID:14675044 PMID:18766458

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

Cbl proto-oncogene like 1

increases expression

Tacrolimus results in increased expression of CBLL1 mRNA

NCBI chr 7:107,744,142...107,761,667
Ensembl chr 7:107,743,073...107,761,667

G

coiled-coil domain containing 88B

increases expression

Tacrolimus results in increased expression of CCDC88B mRNA

NCBI chr11:64,340,204...64,357,534
Ensembl chr11:64,340,204...64,357,534

G

C-C motif chemokine ligand 11

decreases expression

Tacrolimus results in decreased expression of CCL11 mRNA

NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334

G

C-C motif chemokine ligand 15

increases expression

Tacrolimus results in increased expression of CCL6 mRNA

PMID:21865292 PMID:29362864

NCBI chr17:35,997,582...36,001,553
Ensembl chr17:35,996,440...36,001,553

G

C-C motif chemokine ligand 17

increases expression

Tacrolimus results in increased expression of CCL17 mRNA

NCBI chr16:57,396,093...57,416,063
Ensembl chr16:57,404,767...57,416,063

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]
pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]

PMID:12472797 PMID:23958496 PMID:29362864 PMID:36416909

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 20

increases expression

Tacrolimus results in increased expression of CCL20 mRNA

NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564

G

C-C motif chemokine ligand 3

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 5

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CCL5 mRNA
Tacrolimus results in increased expression of CCL5 mRNA
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]

PMID:15948978 PMID:23958496 PMID:25270620

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

C-C motif chemokine ligand 7

increases expression

Tacrolimus results in increased expression of CCL7 mRNA

PMID:23958496 PMID:29362864

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

C-C motif chemokine ligand 8

increases expression

Tacrolimus results in increased expression of CCL8 mRNA

NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402

G

cellular communication network factor 2

multiple interactions

Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]

NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372

G

cyclin A2

increases expression

Tacrolimus results in increased expression of CCNA2 mRNA

NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883

G

cyclin B2

decreases expression
increases expression

Tacrolimus results in decreased expression of CCNB2 mRNA
Tacrolimus results in increased expression of CCNB2 mRNA

PMID:16574167 PMID:29362864

NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045

G

C-C motif chemokine receptor 2

increases expression

Tacrolimus results in increased expression of CCR2 mRNA

NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,864...46,360,940

G

C-C motif chemokine receptor 3

decreases expression

Tacrolimus results in decreased expression of CCR3 mRNA

NCBI chr 3:46,210,696...46,266,706
Ensembl chr 3:46,130,890...46,266,706

G

C-C motif chemokine receptor like 2

increases expression

Tacrolimus results in increased expression of CCRL2 mRNA

NCBI chr 3:46,407,259...46,409,523
Ensembl chr 3:46,407,166...46,412,997

G

CD2 molecule

multiple interactions

Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]

NCBI chr 1:116,754,430...116,769,229
Ensembl chr 1:116,754,430...116,769,229

G

CD44 molecule (IN blood group)

increases expression

Tacrolimus results in increased expression of CD44 mRNA

NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402

G

CD68 molecule

increases expression

Tacrolimus results in increased expression of CD68 mRNA

NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111

G

CD74 molecule

increases expression

Tacrolimus results in increased expression of CD74 mRNA

NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969

G

CD80 molecule

decreases expression

Tacrolimus results in decreased expression of CD80 protein

NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614

G

CD83 molecule

increases expression

Tacrolimus results in increased expression of CD83 mRNA

NCBI chr 6:14,117,256...14,136,918
Ensembl chr 6:14,117,256...14,136,918

G

CD86 molecule

decreases expression

Tacrolimus results in decreased expression of CD86 protein

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

cell division cycle associated 3

increases expression

Tacrolimus results in increased expression of CDCA3 mRNA

NCBI chr12:6,844,798...6,851,286
Ensembl chr12:6,844,793...6,851,292

G

cell division cycle associated 5

increases expression

Tacrolimus results in increased expression of CDCA5 mRNA

NCBI chr11:65,061,093...65,084,040
Ensembl chr11:65,066,300...65,084,164

G

cell division cycle associated 8

increases expression

Tacrolimus results in increased expression of CDCA8 mRNA

NCBI chr 1:37,692,516...37,709,719
Ensembl chr 1:37,692,481...37,709,719

G

cadherin 1

decreases expression

Tacrolimus results in decreased expression of CDH1 protein

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

cadherin 11

increases expression

Tacrolimus results in increased expression of CDH11 mRNA

NCBI chr16:64,943,753...65,123,744
Ensembl chr16:64,943,753...65,126,112

G

cadherin 16

decreases expression

Tacrolimus results in decreased expression of CDH16 mRNA

NCBI chr16:66,908,122...66,918,885
Ensembl chr16:66,908,122...66,918,917

G

cyclin dependent kinase inhibitor 1B

increases expression

Tacrolimus results in increased expression of CDKN1B mRNA

NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369

G

CCAAT enhancer binding protein alpha

increases expression

Tacrolimus results in increased expression of CEBPA mRNA

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

centromere protein W

increases expression

Tacrolimus results in increased expression of CENPW mRNA

NCBI chr 6:126,340,115...126,483,320
Ensembl chr 6:126,340,115...126,348,875

G

complement factor I

increases expression

Tacrolimus results in increased expression of CFI mRNA

NCBI chr 4:109,730,982...109,801,999
Ensembl chr 4:109,731,008...109,802,150

G

cytoskeleton associated protein 2

increases expression

Tacrolimus results in increased expression of CKAP2 mRNA

NCBI chr13:52,455,478...52,476,627
Ensembl chr13:52,455,429...52,476,628

G

cytoskeleton associated protein 4

increases expression

Tacrolimus results in increased expression of CKAP4 mRNA

NCBI chr12:106,237,881...106,248,020
Ensembl chr12:106,237,881...106,304,279

G

claudin 1

decreases expression

Tacrolimus results in decreased expression of CLDN1 mRNA

NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446

G

claudin 4

increases expression

Tacrolimus results in increased expression of CLDN4 mRNA

NCBI chr 7:73,830,996...73,832,690
Ensembl chr 7:73,799,542...73,832,690

G

claudin 7

increases expression

Tacrolimus results in increased expression of CLDN7 mRNA

NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983

G

C-type lectin domain containing 7A

increases expression

Tacrolimus results in increased expression of CLEC7A mRNA

NCBI chr12:10,116,777...10,130,304
Ensembl chr12:10,116,777...10,130,258

G

CDC like kinase 3

increases expression

Tacrolimus results in increased expression of CLK3 mRNA

NCBI chr15:74,608,372...74,630,201
Ensembl chr15:74,598,500...74,645,414

G

clusterin

increases expression

Tacrolimus results in increased expression of CLU mRNA

NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700

G

cochlin

increases expression

Tacrolimus results in increased expression of COCH mRNA

NCBI chr14:30,874,559...30,895,615
Ensembl chr14:30,874,514...30,895,065

G

collagen type I alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL1A1 mRNA

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type I alpha 2 chain

increases expression

Tacrolimus results in increased expression of COL1A2 mRNA

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

collagen type III alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL3A1 mRNA

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

COP9 signalosome subunit 8

increases expression

Tacrolimus results in increased expression of COPS8 mRNA

NCBI chr 2:237,085,889...237,100,474
Ensembl chr 2:237,085,882...237,100,474

G

ceruloplasmin

increases expression

Tacrolimus results in increased expression of CP mRNA

NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829

G

cAMP responsive element binding protein 3 like 3

decreases expression

Tacrolimus results in decreased expression of CREB3L3 mRNA

NCBI chr19:4,153,631...4,173,054
Ensembl chr19:4,153,631...4,173,054

G

cysteine rich with EGF like domains 2

increases expression

Tacrolimus results in increased expression of CRELD2 mRNA

NCBI chr22:49,918,634...49,927,537
Ensembl chr22:49,918,167...49,927,540

G

colony stimulating factor 1

increases expression

Tacrolimus results in increased expression of CSF1 mRNA

NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992

G

colony stimulating factor 2

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CSF2 protein
Tacrolimus results in increased expression of CSF2 mRNA
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein]

PMID:1376361 PMID:11407316 PMID:23958496

NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170

G

colony stimulating factor 2 receptor subunit beta

increases expression

Tacrolimus results in increased expression of CSF2RB2 mRNA

NCBI chr22:36,913,628...36,940,439
Ensembl chr22:36,913,628...36,940,439

G

cathepsin L

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTSL protein]
Tacrolimus results in increased expression of CTSL mRNA

PMID:18172886 PMID:21865292 PMID:25270620

NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469

G

C-X-C motif chemokine ligand 10

increases expression

Tacrolimus results in increased expression of CXCL10 mRNA

PMID:21865292 PMID:23958496 PMID:25270620

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 11

increases expression

Tacrolimus results in increased expression of CXCL11 mRNA

NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415

G

C-X-C motif chemokine ligand 8

multiple interactions

Tacrolimus inhibits the reaction [cinnamaldehyde results in increased expression of CXCL8 mRNA]; Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL8 protein]; Tacrolimus inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CXCL8 mRNA]

PMID:20090409 PMID:36416909

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome b-245 alpha chain

multiple interactions
increases expression

Ramipril inhibits the reaction [Tacrolimus results in increased expression of CYBA mRNA]

NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083

G

cytochrome P450 family 27 subfamily B member 1

increases expression

Tacrolimus results in increased expression of CYP27B1 mRNA

NCBI chr12:57,762,334...57,767,078
Ensembl chr12:57,762,334...57,768,986

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions

CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]

PMID:15010519 PMID:15285851 PMID:17377957

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 3 subfamily A member 4

affects metabolic processing
decreases methylation
increases metabolic processing
multiple interactions

CYP3A4 protein affects the metabolism of Tacrolimus
CYP3A4 protein results in decreased methylation of Tacrolimus
CYP3A4 protein results in increased metabolism of Tacrolimus
Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]

PMID:15010519 PMID:15855244 PMID:15919446 PMID:15951320 PMID:15964336

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 5

multiple interactions
decreases methylation
affects metabolic processing
affects response to substance

CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]
CYP3A5 protein results in decreased methylation of Tacrolimus
CYP3A5 gene polymorphism affects the metabolism of Tacrolimus; CYP3A5 gene SNP affects the metabolism of Tacrolimus; CYP3A5 protein affects the metabolism of Tacrolimus; CYP3A5 protein polymorphism affects the metabolism of Tacrolimus
CYP3A5 gene affects the susceptibility to Tacrolimus; CYP3A5 polymorphism affects the susceptibility to Tacrolimus

PMID:15502717 PMID:15723604 PMID:15729180 PMID:15808586 PMID:15919447 More...

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

cytochrome P450 family 3 subfamily A member 51, pseudogene

affects metabolic processing

CYP3A51P gene SNP affects the metabolism of Tacrolimus

NCBI chr 7:99,685,024...99,700,120
Ensembl chr 7:99,685,145...99,700,034

G

cytochrome P450 family 3 subfamily A member 7

decreases methylation

CYP3A7 protein results in decreased methylation of Tacrolimus

NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196

G

decorin

increases expression

Tacrolimus results in increased expression of DCN mRNA

NCBI chr12:91,140,484...91,182,817
Ensembl chr12:91,140,484...91,183,217

G

DNA damage inducible transcript 3

multiple interactions
increases expression

salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
Tacrolimus results in increased expression of DDIT3 mRNA

PMID:23958496 PMID:25270620

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

DNA damage inducible transcript 4 like

decreases expression

Tacrolimus results in decreased expression of DDIT4L mRNA

NCBI chr 4:100,185,870...100,190,468
Ensembl chr 4:100,185,870...100,190,782

G

24-dehydrocholesterol reductase

decreases expression

Tacrolimus results in decreased expression of DHCR24 mRNA

NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195

G

DnaJ heat shock protein family (Hsp40) member C30

decreases expression

Tacrolimus results in decreased expression of DNAJC30 mRNA

NCBI chr 7:73,680,918...73,683,453
Ensembl chr 7:73,680,918...73,683,453

G

dynamin 1 like

multiple interactions

PINK1 protein affects the reaction [Tacrolimus results in increased phosphorylation of DNM1L protein]
Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:19492085 PMID:26318285

NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650

G

double C2 domain alpha

decreases expression

Tacrolimus results in decreased expression of DOC2A mRNA

NCBI chr16:30,005,514...30,023,228
Ensembl chr16:30,005,514...30,023,270

G

dedicator of cytokinesis 10

increases expression

Tacrolimus results in increased expression of DOCK10 mRNA

NCBI chr 2:224,765,090...225,042,468
Ensembl chr 2:224,765,090...225,042,468

G

dipeptidyl peptidase 4

increases activity
multiple interactions

Tacrolimus results in increased activity of DPP4 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of DPP4 protein]

NCBI chr 2:161,992,245...162,074,215
Ensembl chr 2:161,992,245...162,074,394

G

dopamine receptor D2

affects activity
multiple interactions

Tacrolimus affects the activity of DRD2 protein
Sulpiride inhibits the reaction [Tacrolimus affects the activity of DRD2 protein]

NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691

G

enoyl-CoA hydratase 1

decreases expression

Tacrolimus results in decreased expression of ECH1 mRNA

NCBI chr19:38,815,422...38,831,794
Ensembl chr19:38,815,422...38,831,841

G

ER degradation enhancing alpha-mannosidase like protein 1

increases expression

Tacrolimus results in increased expression of EDEM1 mRNA

NCBI chr 3:5,187,707...5,219,958
Ensembl chr 3:5,187,646...5,219,958

G

endothelin 1

increases expression

Tacrolimus results in increased expression of EDN1 mRNA; Tacrolimus results in increased expression of EDN1 protein

PMID:9517403 PMID:9931093

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

endothelin receptor type A

increases activity
increases expression

Tacrolimus results in increased activity of EDNRA protein
Tacrolimus results in increased expression of EDNRA mRNA

PMID:8587392 PMID:15964565

NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954

G

EGF containing fibulin extracellular matrix protein 2

increases expression

Tacrolimus results in increased expression of EFEMP2 mRNA

NCBI chr11:65,866,441...65,872,800
Ensembl chr11:65,866,441...65,873,592

G

early growth response 1

increases expression

Tacrolimus results in increased expression of EGR1 mRNA

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

early growth response 2

increases expression

Tacrolimus results in increased expression of EGR2 mRNA

NCBI chr10:62,811,996...62,819,167
Ensembl chr10:62,811,996...62,819,167

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein]

NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365

G

elaC ribonuclease Z 2

decreases expression

Tacrolimus results in decreased expression of ELAC2 mRNA

NCBI chr17:12,991,612...13,018,027
Ensembl chr17:12,991,612...13,018,065

G

endoplasmic reticulum to nucleus signaling 1

increases phosphorylation

Tacrolimus results in increased phosphorylation of ERN1 protein

NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819

G

endoplasmic reticulum oxidoreductase 1 alpha

increases expression

Tacrolimus results in increased expression of ERO1A mRNA

NCBI chr14:52,639,915...52,695,558
Ensembl chr14:52,639,915...52,695,900

G

exosome component 4

decreases expression

Tacrolimus results in decreased expression of EXOSC4 mRNA

NCBI chr 8:144,064,056...144,080,648
Ensembl chr 8:144,078,648...144,080,648

G

coagulation factor II thrombin receptor

decreases expression

Tacrolimus results in decreased expression of F2R mRNA

NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770

G

fatty acid binding protein 2

decreases expression

Tacrolimus results in decreased expression of FABP2 mRNA

NCBI chr 4:119,317,250...119,322,138
Ensembl chr 4:119,317,250...119,322,138

G

Fas cell surface death receptor

multiple interactions

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

Fas ligand

decreases secretion

Tacrolimus results in decreased secretion of FASLG protein

NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876

G

fibulin 1

increases expression

Tacrolimus results in increased expression of FBLN1 mRNA

NCBI chr22:45,502,883...45,601,135
Ensembl chr22:45,502,238...45,601,135

G

fibrinogen alpha chain

increases expression

Tacrolimus results in increased expression of FGA mRNA

NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742

G

fibrinogen beta chain

increases expression

Tacrolimus results in increased expression of FGB mRNA

NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807

G

FYVE, RhoGEF and PH domain containing 2

increases expression

Tacrolimus results in increased expression of FGD2 mRNA

NCBI chr 6:37,005,655...37,029,069
Ensembl chr 6:37,005,646...37,029,069

G

fibroblast growth factor 21

decreases expression

Tacrolimus results in decreased expression of FGF21 mRNA

NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333

G

fibrinogen like 2

increases expression

Tacrolimus results in increased expression of FGL2 mRNA

PMID:21865292 PMID:29362864

NCBI chr 7:77,193,369...77,199,819
Ensembl chr 7:77,193,369...77,199,848

G

four and a half LIM domains 2

increases expression

Tacrolimus results in increased expression of FHL2 mRNA

NCBI chr 2:105,357,712...105,438,529
Ensembl chr 2:105,357,712...105,438,513

G

FKBP prolyl isomerase 1A

multiple interactions
increases expression

[Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]; [Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]
Tacrolimus results in increased expression of FKBP1A protein

PMID:10361256 PMID:11041285 PMID:16720724

NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164

G

FKBP prolyl isomerase 5

multiple interactions

Tacrolimus inhibits the reaction [NR3C1 protein binds to FKBP5 protein]

NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583

G

fms related receptor tyrosine kinase 3

increases expression

Tacrolimus results in increased expression of FLT3 mRNA

NCBI chr13:28,003,274...28,100,576
Ensembl chr13:28,003,274...28,100,592

G

flavin containing dimethylaniline monoxygenase 2

increases expression

Tacrolimus results in increased expression of FMO2 mRNA

NCBI chr 1:171,185,208...171,212,686
Ensembl chr 1:171,185,249...171,212,686

G

fibronectin 1

multiple interactions
increases expression

Tacrolimus inhibits the reaction [NPR1 protein affects the expression of FN1 mRNA]
Tacrolimus results in increased expression of FN1 mRNA

PMID:15939815 PMID:29362864

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

fibronectin type III domain containing 3A

increases expression

Tacrolimus results in increased expression of FNDC3A mRNA

NCBI chr13:48,975,291...49,209,779
Ensembl chr13:48,975,912...49,209,779

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of FOS mRNA

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of FOSL1 mRNA

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

guanylate binding protein 1

decreases expression

Tacrolimus results in decreased expression of GBP1 mRNA

NCBI chr 1:89,052,319...89,065,208
Ensembl chr 1:89,051,882...89,065,360

G

GC vitamin D binding protein

decreases expression
increases expression

Tacrolimus results in decreased expression of GC mRNA
Tacrolimus results in increased expression of GC mRNA

PMID:21865292 PMID:29362864

NCBI chr 4:71,741,693...71,805,520
Ensembl chr 4:71,741,696...71,804,041

G

glucagon

multiple interactions
decreases secretion

MK0626 inhibits the reaction [Tacrolimus results in decreased secretion of GCG protein modified form]

NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404

G

GINS complex subunit 2

increases expression

Tacrolimus results in increased expression of GINS2 mRNA

NCBI chr16:85,676,198...85,688,954
Ensembl chr16:85,676,198...85,690,073

G

gap junction protein beta 1

increases expression

Tacrolimus results in increased expression of GJB1 mRNA

NCBI chr X:71,215,239...71,225,516
Ensembl chr X:71,212,811...71,225,516

G

glycine decarboxylase

decreases expression

Tacrolimus results in decreased expression of GLDC mRNA

NCBI chr 9:6,532,467...6,645,729
Ensembl chr 9:6,532,467...6,645,729

G

glucagon like peptide 1 receptor

decreases expression
multiple interactions

Tacrolimus results in decreased expression of GLP1R protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of GLP1R protein]

NCBI chr 6:39,048,781...39,091,303
Ensembl chr 6:39,048,781...39,091,303

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

decreases expression

Tacrolimus results in decreased expression of GPIHBP1 mRNA

NCBI chr 8:143,213,218...143,217,170
Ensembl chr 8:143,213,218...143,217,170

G

GPN-loop GTPase 2

increases expression

Tacrolimus results in increased expression of GPN2 mRNA

NCBI chr 1:26,876,132...26,890,283
Ensembl chr 1:26,876,132...26,890,283

G

glycoprotein nmb

increases expression

Tacrolimus results in increased expression of GPNMB mRNA

NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108

G

granulin precursor

increases expression

Tacrolimus results in increased expression of GRN mRNA

NCBI chr17:44,345,302...44,353,106
Ensembl chr17:44,345,246...44,353,106

G

glycogen synthase kinase 3 alpha

multiple interactions
increases phosphorylation

[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]
Tacrolimus results in increased phosphorylation of GSK3A protein

NCBI chr19:42,230,190...42,242,602
Ensembl chr19:42,226,225...42,242,625

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]
Tacrolimus results in increased phosphorylation of GSK3B protein

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

GTP binding protein 4

decreases expression

Tacrolimus results in decreased expression of GTPBP4 mRNA

NCBI chr10:988,434...1,019,932
Ensembl chr10:988,434...1,019,932

G

guanylate cyclase activator 2A

increases expression

Tacrolimus results in increased expression of GUCA2A mRNA

NCBI chr 1:42,162,690...42,164,745
Ensembl chr 1:42,162,690...42,164,745

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

decreases expression

Tacrolimus results in decreased expression of HADHB mRNA

NCBI chr 2:26,244,939...26,290,465
Ensembl chr 2:26,243,170...26,290,465

G

hepatitis A virus cellular receptor 1

increases expression

Tacrolimus results in increased expression of HAVCR1 mRNA

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

Tacrolimus results in increased expression of HERPUD1 mRNA

PMID:23958496 PMID:25270620

NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864

G

hexosaminidase subunit alpha

increases expression

Tacrolimus results in increased expression of HEXA mRNA

NCBI chr15:72,340,924...72,376,014
Ensembl chr15:72,340,924...72,376,420

G

hepatocyte growth factor-regulated tyrosine kinase substrate

increases expression

Tacrolimus results in increased expression of HGS mRNA

NCBI chr17:81,684,011...81,702,121
Ensembl chr17:81,683,326...81,703,138

G

hexokinase 2

increases expression

Tacrolimus results in increased expression of HK2 mRNA

NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359

G

hexokinase 3

increases expression

Tacrolimus results in increased expression of HK3 mRNA

NCBI chr 5:176,880,869...176,899,346
Ensembl chr 5:176,880,869...176,899,346

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

Tacrolimus results in decreased expression of HMGCS2 mRNA

NCBI chr 1:119,747,996...119,768,932
Ensembl chr 1:119,748,002...119,768,905

G

heme oxygenase 1

increases expression
decreases expression
multiple interactions

Tacrolimus results in increased expression of HMOX1 mRNA; Tacrolimus results in increased expression of HMOX1 protein
Tacrolimus results in decreased expression of HMOX1 protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of HMOX1 protein]

PMID:23958496 PMID:24959755 PMID:26260164 PMID:29362864

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

HNF1 homeobox B

decreases expression

Tacrolimus results in decreased expression of HNF1B mRNA

NCBI chr17:37,686,431...37,745,059
Ensembl chr17:37,686,431...37,745,059

G

hydroxysteroid dehydrogenase like 2

decreases expression

Tacrolimus results in decreased expression of HSDL2 mRNA

NCBI chr 9:112,380,108...112,472,405
Ensembl chr 9:112,380,080...112,472,405

G

heat shock protein family A (Hsp70) member 5

increases expression

Tacrolimus results in increased expression of HSPA5 mRNA

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

heat shock protein family A (Hsp70) member 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Acrylamide results in decreased expression of HSPA8 protein]
Tacrolimus results in increased expression of HSPA8 protein

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

5-hydroxytryptamine receptor 1A

decreases expression

Tacrolimus results in decreased expression of HTR1A protein

NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507

G

5-hydroxytryptamine receptor 1B

decreases expression

Tacrolimus results in decreased expression of HTR1B protein

NCBI chr 6:77,460,924...77,463,491
Ensembl chr 6:77,460,924...77,463,491

G

intercellular adhesion molecule 1

decreases expression
increases expression

Tacrolimus results in decreased expression of ICAM1; Tacrolimus results in decreased expression of ICAM1 protein
Tacrolimus results in increased expression of ICAM1 mRNA

PMID:9794552 PMID:10385251 PMID:23958496

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

inhibitor of DNA binding 1

increases expression

Tacrolimus results in increased expression of ID1 mRNA

PMID:25270620 PMID:29362864

NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515

G

inhibitor of DNA binding 2

increases expression

Tacrolimus results in increased expression of ID2 mRNA

NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461

G

inhibitor of DNA binding 3

increases expression

Tacrolimus results in increased expression of ID3 mRNA

NCBI chr 1:23,557,926...23,559,501
Ensembl chr 1:23,557,926...23,559,501

G

inhibitor of DNA binding 4

increases expression

Tacrolimus results in increased expression of ID4 mRNA

NCBI chr 6:19,837,370...19,842,197
Ensembl chr 6:19,837,370...19,842,197

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Tacrolimus results in decreased expression of IDI1 mRNA

NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119

G

interferon alpha inducible protein 27 like 2

increases expression

Tacrolimus results in increased expression of IFI27L2A mRNA

NCBI chr14:94,127,781...94,129,604
Ensembl chr14:94,127,779...94,130,253

G

interferon gamma

multiple interactions
decreases expression
decreases secretion

[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IFNG mRNA]
Tacrolimus results in decreased expression of IFNG protein
Tacrolimus results in decreased expression of IFNG mRNA; Tacrolimus results in decreased expression of IFNG protein
[Tacrolimus co-treated with TAK 779] results in decreased expression of IFNG protein
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TRP53 protein]
Tacrolimus results in decreased secretion of IFNG protein

PMID:1371491 PMID:8986461 PMID:10205001 PMID:11407316 PMID:11692113 More...

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

insulin like growth factor 1

increases response to substance

IGF1 protein results in increased susceptibility to Tacrolimus

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor binding protein 1

decreases expression
increases expression

Tacrolimus results in decreased expression of IGFBP1 mRNA
Tacrolimus results in increased expression of IGFBP1 mRNA

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

insulin like growth factor binding protein 5

increases expression

Tacrolimus results in increased expression of IGFBP5 mRNA

NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549

G

interleukin 12B

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

interleukin 15 receptor subunit alpha

increases expression

Tacrolimus results in increased expression of IL15RA mRNA

NCBI chr10:5,948,900...5,978,741
Ensembl chr10:5,943,639...5,978,187

G

interleukin 17 receptor A

increases expression

Tacrolimus results in increased expression of IL17RA mRNA

NCBI chr22:17,085,000...17,115,693
Ensembl chr22:17,084,954...17,115,693

G

interleukin 1 beta

increases expression

Tacrolimus results in increased expression of IL1B mRNA

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 1 receptor antagonist

increases expression

Tacrolimus results in increased expression of IL1RN mRNA

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 2

multiple interactions
decreases expression

[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]; Tacrolimus inhibits the reaction [Zinc Sulfate inhibits the reaction [Mitogens results in increased expression of IL2 mRNA]]
Tacrolimus results in decreased expression of IL2 mRNA; Tacrolimus results in decreased expression of IL2 protein
Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of IL2 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]

PMID:1371491 PMID:1614535 PMID:1701765 PMID:1705513 PMID:8986461 More...

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 23 subunit alpha

increases expression

Tacrolimus results in increased expression of IL23A mRNA

NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410

G

interleukin 2 receptor subunit alpha

decreases expression

Tacrolimus results in decreased expression of IL2RA protein

NCBI chr10:6,010,689...6,062,367
Ensembl chr10:6,010,689...6,062,370

G

interleukin 3

decreases expression
multiple interactions

Tacrolimus results in decreased expression of IL3 protein
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL3 protein]

PMID:1376361 PMID:11407316

NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204

G

interleukin 4

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL4 protein]
Tacrolimus results in decreased expression of IL4 mRNA; Tacrolimus results in decreased expression of IL4 protein
Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [bisphenol A results in increased expression of IL4 protein]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol results in increased expression of IL4 protein]

PMID:1371491 PMID:10685002 PMID:11407316 PMID:12709020 PMID:16368244

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 5

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL5 protein]
Tacrolimus results in decreased expression of IL5 mRNA; Tacrolimus results in decreased expression of IL5 protein

PMID:1371491 PMID:7540862 PMID:11407316 PMID:15948978

NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838

G

interleukin 6

multiple interactions
increases expression
decreases expression

[Tacrolimus co-treated with quinapril] results in decreased expression of IL6 protein; [Tacrolimus co-treated with quinapril] results in increased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in decreased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in increased expression of IL6 protein
Tacrolimus results in increased expression of IL6 mRNA
parthenolide inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA]
Tacrolimus results in increased expression of IL6 protein
Tacrolimus results in decreased expression of IL6 protein

PMID:16549154 PMID:23958496

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

IMP U3 small nucleolar ribonucleoprotein 4

decreases expression

Tacrolimus results in decreased expression of IMP4 mRNA

NCBI chr 2:130,342,897...130,347,967
Ensembl chr 2:130,342,877...130,347,967

G

INO80 complex subunit E

decreases expression

Tacrolimus results in decreased expression of INO80E mRNA

NCBI chr16:29,996,241...30,005,791
Ensembl chr16:29,995,715...30,005,793

G

insulin

decreases expression

Tacrolimus results in decreased expression of INS protein

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

INS-IGF2 readthrough

multiple interactions
decreases expression

MK0626 inhibits the reaction [Tacrolimus results in decreased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

interleukin 1 receptor associated kinase 1

increases phosphorylation

Tacrolimus results in increased phosphorylation of IRAK1 protein

NCBI chr X:154,010,507...154,019,902
Ensembl chr X:154,010,506...154,019,902

G

integrin subunit alpha L

decreases expression

Tacrolimus results in decreased expression of ITGAL

NCBI chr16:30,472,742...30,523,185
Ensembl chr16:30,472,658...30,523,567

G

Janus kinase 2

increases phosphorylation

Tacrolimus results in increased phosphorylation of JAK2 protein

NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

Tacrolimus results in decreased expression of JUN protein

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

Tacrolimus results in increased expression of JUNB mRNA

NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315

G

kinesin associated protein 3

decreases expression

Tacrolimus results in decreased expression of KIFAP3 mRNA

NCBI chr 1:169,921,329...170,085,184
Ensembl chr 1:169,921,326...170,085,208

G

kinesin family member C1

decreases expression

Tacrolimus results in decreased expression of KIFC1 mRNA

NCBI chr 6:33,391,461...33,409,896
Ensembl chr 6:33,391,823...33,409,896

G

KLF transcription factor 5

increases expression

Tacrolimus results in increased expression of KLF5 mRNA

NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541

G

KLF transcription factor 6

increases expression

Tacrolimus results in increased expression of KLF6 mRNA

NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281

G

kallikrein related peptidase 3

increases expression

Tacrolimus results in increased expression of KLK1C10 mRNA

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

KRAS proto-oncogene, GTPase

increases expression

Tacrolimus results in increased expression of KRAS mRNA

NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936

G

keratin 20

increases expression

Tacrolimus results in increased expression of KRT20 mRNA

NCBI chr17:40,875,889...40,885,242
Ensembl chr17:40,875,889...40,885,242

G

laminin subunit gamma 2

increases expression

Tacrolimus results in increased expression of LAMC2 mRNA

NCBI chr 1:183,186,264...183,258,968
Ensembl chr 1:183,186,238...183,245,127

G

lipopolysaccharide binding protein

increases expression

Tacrolimus results in increased expression of LBP mRNA

NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013

G

lipocalin 2

increases expression

Tacrolimus results in increased expression of LCN2 mRNA

PMID:21865292 PMID:29362864

NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453

G

lipoic acid synthetase

decreases expression

Tacrolimus results in decreased expression of LIAS mRNA

NCBI chr 4:39,459,056...39,479,506
Ensembl chr 4:39,459,004...39,485,109

G

LIF interleukin 6 family cytokine

increases expression

Tacrolimus results in increased expression of LIF mRNA

NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759

G

LIM domain kinase 1

increases expression

Tacrolimus results in increased expression of LIMK1 mRNA

NCBI chr 7:74,083,804...74,122,525
Ensembl chr 7:74,082,933...74,122,525

G

LLGL scribble cell polarity complex component 1

increases expression

Tacrolimus results in increased expression of LLGL1 mRNA

NCBI chr17:18,225,635...18,244,875
Ensembl chr17:18,225,635...18,244,875

G

lymphotoxin alpha

multiple interactions

Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of LTA protein]

NCBI chr 6:31,560,610...31,574,324
Ensembl chr 6:31,572,054...31,574,324

G

lactotransferrin

increases expression

Tacrolimus results in increased expression of LTF mRNA

NCBI chr 3:46,435,645...46,485,234
Ensembl chr 3:46,435,645...46,485,234

G

lymphocyte antigen 86

increases expression

Tacrolimus results in increased expression of LY86 mRNA

NCBI chr 6:6,588,720...6,654,982
Ensembl chr 6:6,588,108...6,654,983

G

lymphatic vessel endothelial hyaluronan receptor 1

decreases expression

Tacrolimus results in decreased expression of LYVE1 mRNA

NCBI chr11:10,556,966...10,568,665
Ensembl chr11:10,556,966...10,611,689

G

MAF bZIP transcription factor F

increases expression

Tacrolimus results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

MAF bZIP transcription factor K

increases expression

Tacrolimus results in increased expression of MAFK mRNA

NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043

G

mesencephalic astrocyte derived neurotrophic factor

increases expression

Tacrolimus results in increased expression of MANF mRNA

NCBI chr 3:51,385,291...51,389,397
Ensembl chr 3:51,385,291...51,389,397

G

mitogen-activated protein kinase kinase kinase 7

increases phosphorylation

Tacrolimus results in increased phosphorylation of MAP3K7 protein

NCBI chr 6:90,513,579...90,587,072
Ensembl chr 6:90,513,573...90,587,086

G

mitogen-activated protein kinase 8

decreases activity
multiple interactions

Tacrolimus results in decreased activity of MAPK8 protein
Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of MAPK8 protein]

NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360

G

muscleblind like splicing regulator 2

decreases expression

Tacrolimus results in decreased expression of MBNL2 mRNA

NCBI chr13:97,141,834...97,394,120
Ensembl chr13:97,221,434...97,394,120

G

melanoma cell adhesion molecule

decreases expression

Tacrolimus results in decreased expression of MCAM mRNA

NCBI chr11:119,308,529...119,317,130
Ensembl chr11:119,308,529...119,321,521

G

microspherule protein 1

decreases expression

Tacrolimus results in decreased expression of MCRS1 mRNA

NCBI chr12:49,558,299...49,568,142
Ensembl chr12:49,556,544...49,568,145

G

methyltransferase 1, tRNA methylguanosine

increases expression

Tacrolimus results in increased expression of METTL1 mRNA

NCBI chr12:57,768,471...57,772,105
Ensembl chr12:57,768,471...57,772,119

G

major facilitator superfamily domain containing 1

increases expression

Tacrolimus results in increased expression of MFSD1 mRNA

NCBI chr 3:158,802,054...158,829,716
Ensembl chr 3:158,732,198...158,829,719

G

monoglyceride lipase

decreases expression

Tacrolimus results in decreased expression of MGLL mRNA

NCBI chr 3:127,689,066...127,823,185
Ensembl chr 3:127,689,062...128,052,190

G

microRNA 146a

increases expression

Tacrolimus results in increased expression of MIR146 mRNA

NCBI chr 5:160,485,352...160,485,450
Ensembl chr 5:160,485,352...160,485,450

G

microRNA 146b

increases expression

Tacrolimus results in increased expression of MIR146B mRNA

NCBI chr10:102,436,512...102,436,584
Ensembl chr10:102,436,512...102,436,584

G

microRNA 193a

decreases expression

Tacrolimus results in decreased expression of MIR193A mRNA

NCBI chr17:31,559,996...31,560,083
Ensembl chr17:31,559,996...31,560,083

G

microRNA 199b

increases expression

Tacrolimus results in increased expression of MIR199B mRNA

NCBI chr 9:128,244,721...128,244,830
Ensembl chr 9:128,244,721...128,244,830

G

microRNA 200b

decreases expression

Tacrolimus results in decreased expression of MIR200B mRNA

NCBI chr 1:1,167,104...1,167,198
Ensembl chr 1:1,167,104...1,167,198

G

microRNA 21

increases expression

Tacrolimus results in increased expression of MIR21A mRNA

NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337

G

microRNA 214

increases expression

Tacrolimus results in increased expression of MIR214 mRNA

NCBI chr 1:172,138,798...172,138,907
Ensembl chr 1:172,138,798...172,138,907

G

microRNA 34b

increases expression

Tacrolimus results in increased expression of MIR34B mRNA

NCBI chr11:111,512,938...111,513,021
Ensembl chr11:111,512,938...111,513,021

G

microRNA 551b

decreases expression

Tacrolimus results in decreased expression of MIR551B mRNA

NCBI chr 3:168,551,854...168,551,949
Ensembl chr 3:168,551,854...168,551,949

G

microRNA 574

increases expression

Tacrolimus results in increased expression of MIR574 mRNA

NCBI chr 4:38,868,032...38,868,127
Ensembl chr 4:38,868,032...38,868,127

G

MOB family member 4, phocein

increases expression

Tacrolimus results in increased expression of MOB4 mRNA

NCBI chr 2:197,515,554...197,553,699
Ensembl chr 2:197,515,571...197,553,699

G

myeloperoxidase

multiple interactions
decreases expression

Tacrolimus inhibits the reaction [Indomethacin results in increased activity of MPO protein]
Tacrolimus results in decreased expression of MPO protein

PMID:9655420 PMID:17202747

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

mitochondrial rRNA methyltransferase 3

decreases expression

Tacrolimus results in decreased expression of MRM3 mRNA

NCBI chr17:782,353...792,509
Ensembl chr17:782,353...792,509

G

membrane spanning 4-domains A6A

increases expression

Tacrolimus results in increased expression of MS4A6C mRNA

NCBI chr11:60,171,607...60,184,666
Ensembl chr11:60,172,015...60,184,666

G

mesothelin

increases expression

Tacrolimus results in increased expression of MSLN mRNA

NCBI chr16:760,734...768,865
Ensembl chr16:760,734...768,865

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Tacrolimus results in increased expression of MYC mRNA

PMID:21865292 PMID:23958496

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

N-acylethanolamine acid amidase

increases expression

Tacrolimus results in increased expression of NAAA mRNA

NCBI chr 4:75,910,655...75,941,013
Ensembl chr 4:75,913,660...75,941,013

G

NCK associated protein 1 like

increases expression

Tacrolimus results in increased expression of NCKAP1L mRNA

NCBI chr12:54,497,752...54,548,243
Ensembl chr12:54,497,752...54,548,243

G

natural cytotoxicity triggering receptor 3

increases expression

Tacrolimus results in increased expression of NCR3

NCBI chr 6:31,588,895...31,593,006
Ensembl chr 6:31,588,895...31,593,006

G

N-myc downstream regulated 1

increases expression

Tacrolimus results in increased expression of NDRG1 mRNA

NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022

G

nuclear factor of activated T cells 3

multiple interactions

Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [Thapsigargin affects the localization of and results in increased activity of NFATC3 protein]

PMID:10339586 PMID:12709020

NCBI chr16:68,085,370...68,229,259
Ensembl chr16:68,084,751...68,229,259

G

nuclear factor of activated T cells 4

multiple interactions

Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [Phenylephrine results in increased localization of NFATC4 protein]

NCBI chr14:24,366,911...24,379,604
Ensembl chr14:24,365,673...24,379,604

G

NFE2 like bZIP transcription factor 2

increases expression

Tacrolimus results in increased expression of NFE2L2 protein

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of NFKB1 protein]
Tacrolimus results in increased expression of NFKB1 mRNA

PMID:18172213 PMID:18172886 PMID:23958496

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

nuclear factor kappa B subunit 2

increases expression

Tacrolimus results in increased expression of NFKB2 mRNA

NCBI chr10:102,394,110...102,402,529
Ensembl chr10:102,394,110...102,402,524

G

NFKB inhibitor alpha

decreases degradation
increases phosphorylation
multiple interactions

Tacrolimus results in decreased degradation of NFKBIA protein
Tacrolimus results in increased phosphorylation of NFKBIA protein
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased phosphorylation of NFKBIA protein]

PMID:16181452 PMID:23958496

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NFKB inhibitor beta

multiple interactions

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NFKBIB protein]

PMID:18172213 PMID:18172886

NCBI chr19:38,899,666...38,908,889
Ensembl chr19:38,899,700...38,908,893

G

NFKB inhibitor epsilon

increases expression

Tacrolimus results in increased expression of NFKBIE mRNA

NCBI chr 6:44,258,166...44,265,551
Ensembl chr 6:44,258,166...44,265,788

G

nerve growth factor

multiple interactions

NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 mRNA]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 protein]

PMID:17385075 PMID:23825664

NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770

G

nucleolar protein 8

increases expression

Tacrolimus results in increased expression of NOL8 mRNA

NCBI chr 9:92,297,358...92,325,350
Ensembl chr 9:92,297,358...92,325,636

G

nitric oxide synthase 1

multiple interactions

Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of NOS1 protein]

NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170

G

nitric oxide synthase 2

multiple interactions

Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]
Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of NOS2 protein]; Tacrolimus inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]
Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

PMID:12144947 PMID:17202747 PMID:20149694 PMID:27246103

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

increases expression
decreases expression
decreases activity

Tacrolimus results in increased expression of NOS3 mRNA
Tacrolimus results in decreased expression of NOS3 mRNA
Tacrolimus results in decreased activity of NOS3 protein

PMID:9931093 PMID:12352326

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NADPH oxidase 1

increases expression

Tacrolimus results in increased expression of NOX1 mRNA

NCBI chr X:100,843,324...100,874,359
Ensembl chr X:100,843,324...100,874,359

G

natriuretic peptide A

multiple interactions

Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPA mRNA]

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

natriuretic peptide B

multiple interactions

Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPB mRNA]

NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945

G

natriuretic peptide receptor 1

multiple interactions

Tacrolimus inhibits the reaction [NPR1 protein affects the expression of FN1 mRNA]; Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPA mRNA]; Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPB mRNA]

NCBI chr 1:153,678,688...153,693,992
Ensembl chr 1:153,678,688...153,693,992

G

nuclear receptor subfamily 3 group C member 1

multiple interactions
increases activity

Tacrolimus inhibits the reaction [NR3C1 protein binds to FKBP5 protein]; Tacrolimus promotes the reaction [Dexamethasone binds to NR3C1 protein]; Tacrolimus promotes the reaction [NR3C1 protein binds to PPP5C protein]
Tacrolimus results in increased activity of NR3C1 protein

NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512

G

osteoglycin

increases expression

Tacrolimus results in increased expression of OGN mRNA

PMID:21865292 PMID:29362864

NCBI chr 9:92,383,268...92,404,699
Ensembl chr 9:92,383,268...92,404,696

G

olfactomedin like 3

increases expression

Tacrolimus results in increased expression of OLFML3 mRNA

NCBI chr 1:113,979,474...113,982,253
Ensembl chr 1:113,979,391...114,035,572

G

pannexin 1

increases expression

Tacrolimus results in increased expression of PANX1 mRNA

NCBI chr11:94,128,841...94,181,968
Ensembl chr11:94,128,841...94,181,968

G

PDZ binding kinase

increases expression

Tacrolimus results in increased expression of PBK mRNA

NCBI chr 8:27,809,624...27,837,817
Ensembl chr 8:27,809,624...27,838,082

G

poly(rC) binding protein 4

decreases expression

Tacrolimus results in decreased expression of PCBP4 mRNA

NCBI chr 3:51,957,454...51,967,466
Ensembl chr 3:51,957,454...51,974,016

G

proliferating cell nuclear antigen

multiple interactions

Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]; Tacrolimus affects the reaction [Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]]

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

procollagen C-endopeptidase enhancer

decreases expression

Tacrolimus results in decreased expression of PCOLCE mRNA

NCBI chr 7:100,602,363...100,608,175
Ensembl chr 7:100,602,363...100,608,175

G

programmed cell death 2

increases expression

Tacrolimus results in increased expression of PDCD2 mRNA

NCBI chr 6:170,575,295...170,584,637
Ensembl chr 6:170,575,295...170,584,692

G

platelet derived growth factor receptor alpha

increases expression

Tacrolimus results in increased expression of PDGFRA mRNA

NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245

G

protein disulfide isomerase family A member 4

increases expression

Tacrolimus results in increased expression of PDIA4 mRNA

NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662

G

protein disulfide isomerase family A member 6

increases expression

Tacrolimus results in increased expression of PDIA6 mRNA

NCBI chr 2:10,783,391...10,837,712
Ensembl chr 2:10,783,391...10,837,977

G

pleckstrin homology like domain family A member 1

increases expression

Tacrolimus results in increased expression of PHLDA1 mRNA

NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776

G

phosphotyrosine interaction domain containing 1

increases expression

Tacrolimus results in increased expression of PID1 mRNA

NCBI chr 2:229,023,973...229,271,287
Ensembl chr 2:228,850,526...229,271,287

G

PTEN induced kinase 1

multiple interactions

PINK1 protein affects the reaction [Tacrolimus results in increased phosphorylation of DNM1L protein]

NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511

G

protein kinase, membrane associated tyrosine/threonine 1

increases expression

Tacrolimus results in increased expression of PKMYT1 mRNA

NCBI chr16:2,972,808...2,980,446
Ensembl chr16:2,968,024...2,980,479

G

plakophilin 4

decreases expression

Tacrolimus results in decreased expression of PKP4 mRNA

NCBI chr 2:158,456,952...158,681,429
Ensembl chr 2:158,456,952...158,682,879

G

phospholipase A2 group XIIA

increases expression

Tacrolimus results in increased expression of PLA2G12A mRNA

NCBI chr 4:109,709,989...109,730,070
Ensembl chr 4:109,709,989...109,730,070

G

plasminogen activator, tissue type

decreases expression

Tacrolimus results in decreased expression of PLAT mRNA

NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709

G

phospholipase B domain containing 2

decreases expression

Tacrolimus results in decreased expression of PLBD2 mRNA

NCBI chr12:113,358,587...113,391,629
Ensembl chr12:113,358,566...113,391,629

G

cytochrome p450 oxidoreductase

affects response to substance

POR polymorphism affects the susceptibility to Tacrolimus

NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855

G

peroxisome proliferator activated receptor alpha

affects response to substance

PPARA polymorphism affects the susceptibility to Tacrolimus

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor gamma

multiple interactions

[Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

periplakin

increases expression

Tacrolimus results in increased expression of PPL mRNA

NCBI chr16:4,882,507...4,937,148
Ensembl chr16:4,882,507...4,960,741

G

protein phosphatase 1 regulatory subunit 15A

increases expression

Tacrolimus results in increased expression of PPP1R15A mRNA

NCBI chr19:48,872,421...48,876,058
Ensembl chr19:48,872,212...48,876,059

G

protein phosphatase 3 catalytic subunit alpha

multiple interactions
decreases activity

[Tacrolimus results in decreased activity of PPP3CA protein] which results in decreased susceptibility to Thapsigargin

PMID:10898953 PMID:19553475

NCBI chr 4:101,023,418...101,347,526
Ensembl chr 4:101,023,409...101,348,278

G

protein phosphatase 5 catalytic subunit

multiple interactions

Tacrolimus promotes the reaction [NR3C1 protein binds to PPP5C protein]

NCBI chr19:46,347,087...46,390,975
Ensembl chr19:46,347,087...46,392,981

G

prolylcarboxypeptidase

increases expression

Tacrolimus results in increased expression of PRCP mRNA

NCBI chr11:82,822,936...82,901,644
Ensembl chr11:82,822,936...82,970,584

G

prolactin receptor

decreases expression

Tacrolimus results in decreased expression of PRLR mRNA

NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487

G

proteasome 20S subunit beta 10

increases expression

Tacrolimus results in increased expression of PSMB10 mRNA

NCBI chr16:67,934,506...67,936,850
Ensembl chr16:67,934,506...67,936,864

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Tacrolimus inhibits the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA]
Tacrolimus results in increased expression of PTGS2 mRNA

PMID:12493747 PMID:23958496

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

protein tyrosine phosphatase non-receptor type 5

decreases activity

Tacrolimus results in decreased activity of PTPN5 protein

NCBI chr11:18,727,928...18,792,721
Ensembl chr11:18,727,928...18,792,721

G

protein tyrosine phosphatase receptor type Z1

increases expression

Tacrolimus results in increased expression of PTPRZ1 mRNA

NCBI chr 7:121,873,161...122,062,036
Ensembl chr 7:121,873,089...122,062,036

G

RAB4A, member RAS oncogene family

increases expression

Tacrolimus results in increased expression of RAB4A mRNA

NCBI chr 1:229,271,111...229,305,894
Ensembl chr 1:229,271,062...229,305,894

G

Rac family small GTPase 1

increases expression

Tacrolimus results in increased expression of RAC1 mRNA

NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967

G

receptor activity modifying protein 1

increases expression

Tacrolimus results in increased expression of RAMP1 mRNA

NCBI chr 2:237,858,880...237,912,106
Ensembl chr 2:237,858,893...237,912,106

G

regulator of chromosome condensation 1

decreases expression

Tacrolimus results in decreased expression of RCC1 mRNA

NCBI chr 1:28,506,043...28,538,989
Ensembl chr 1:28,505,943...28,539,300

G

REST corepressor 2

decreases expression

Tacrolimus results in decreased expression of RCOR2 mRNA

NCBI chr11:63,911,230...63,927,762
Ensembl chr11:63,911,230...63,917,164

G

REL proto-oncogene, NF-kB subunit

multiple interactions

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of REL protein]

NCBI chr 2:60,881,574...60,931,612
Ensembl chr 2:60,881,491...60,931,612

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Tacrolimus co-treated with Thapsigargin] affects the localization of and results in increased activity of RELA protein; Tacrolimus affects the localization of and results in increased activity of RELA protein; Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of RELA protein]; Tacrolimus results in increased phosphorylation of and affects the localization of RELA protein

PMID:10339586 PMID:18172886 PMID:23958496

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

RELB proto-oncogene, NF-kB subunit

increases expression

Tacrolimus results in increased expression of RELB mRNA

NCBI chr19:45,001,464...45,038,192
Ensembl chr19:45,001,461...45,038,192

G

renin

multiple interactions
increases expression
decreases activity

nilvadipine inhibits the reaction [Tacrolimus results in increased expression of REN protein]
Tacrolimus results in increased expression of REN mRNA; Tacrolimus results in increased expression of REN protein
Tacrolimus results in decreased activity of REN protein

PMID:7509514 PMID:7532090 PMID:7533848 PMID:12469222 PMID:21865292

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

renin binding protein

increases expression

Tacrolimus results in increased expression of RENBP mRNA

NCBI chr X:153,935,269...153,944,643
Ensembl chr X:153,935,269...153,944,687

G

regucalcin

decreases expression

Tacrolimus results in decreased expression of RGN mRNA

NCBI chr X:47,078,443...47,093,313
Ensembl chr X:47,078,355...47,093,314

G

regulator of G protein signaling 16

increases expression

Tacrolimus results in increased expression of RGS16 mRNA

NCBI chr 1:182,598,623...182,604,389
Ensembl chr 1:182,598,623...182,604,389

G

RHEB like 1

increases expression

Tacrolimus results in increased expression of RHEBL1 mRNA

NCBI chr12:49,064,676...49,069,979
Ensembl chr12:49,064,676...49,070,025

G

ras homolog family member U

increases expression

Tacrolimus results in increased expression of RHOU mRNA

NCBI chr 1:228,644,647...228,746,669
Ensembl chr 1:228,735,479...228,746,664

G

ribonuclease A family member 3

increases expression

Tacrolimus results in increased expression of EAR1 mRNA

NCBI chr14:20,891,385...20,892,348
Ensembl chr14:20,891,385...20,892,348

G

ribophorin I

increases expression

Tacrolimus results in increased expression of RPN1 mRNA

NCBI chr 3:128,619,969...128,650,818
Ensembl chr 3:128,619,969...128,681,075

G

ribosomal protein S6

multiple interactions

Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]

NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236

G

ribosomal RNA processing 9, U3 small nucleolar RNA binding protein

decreases expression

Tacrolimus results in decreased expression of RRP9 mRNA

NCBI chr 3:51,933,429...51,941,904
Ensembl chr 3:51,933,429...51,941,904

G

RUNX family transcription factor 2

decreases expression

Tacrolimus results in decreased expression of RUNX2 mRNA

NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349

G

ryanodine receptor 1

multiple interactions

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RYR1 protein]

PMID:18172213 PMID:18172886

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

S100 calcium binding protein A6

increases expression

Tacrolimus results in increased expression of S100A6 mRNA

NCBI chr 1:153,534,599...153,535,991
Ensembl chr 1:153,534,599...153,536,244

G

secretin

increases expression

Tacrolimus results in increased expression of SCT mRNA

NCBI chr11:626,309...627,181
Ensembl chr11:626,309...627,181

G

stromal cell derived factor 2 like 1

increases expression

Tacrolimus results in increased expression of SDF2L1 mRNA

NCBI chr22:21,642,302...21,644,299
Ensembl chr22:21,642,302...21,644,299

G

SEH1 like nucleoporin

increases expression

Tacrolimus results in increased expression of SEH1L mRNA

NCBI chr18:12,948,011...12,987,536
Ensembl chr18:12,947,133...12,987,536

G

selectin E

increases expression

Tacrolimus results in increased expression of SELE mRNA

NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705

G

selenoprotein S

increases expression

Tacrolimus results in increased expression of SELENOS mRNA

NCBI chr15:101,270,809...101,277,485
Ensembl chr15:101,270,817...101,277,500

G

serine incorporator 3

decreases expression

Tacrolimus results in decreased expression of SERINC3 mRNA

NCBI chr20:44,496,221...44,522,070
Ensembl chr20:44,496,221...44,522,085

G

stress associated endoplasmic reticulum protein 1

increases expression

Tacrolimus results in increased expression of SERP1 mRNA

NCBI chr 3:150,541,998...150,546,496
Ensembl chr 3:150,541,998...150,603,228

G

serpin family A member 3

increases expression

Tacrolimus results in increased expression of SERPINA3N mRNA

NCBI chr14:94,612,391...94,624,053
Ensembl chr14:94,612,384...94,624,055

G

serpin family B member 9

increases expression

Tacrolimus results in increased expression of SERPINB9 mRNA

NCBI chr 6:2,887,270...2,903,309
Ensembl chr 6:2,887,270...2,903,309

G

serpin family E member 1

increases expression
multiple interactions

Tacrolimus results in increased expression of SERPINE1 mRNA
Tacrolimus inhibits the reaction [Mercuric Chloride results in increased expression of SERPINE1 protein]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 mRNA]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 protein]

PMID:9422427 PMID:14620542 PMID:21865292 PMID:23825664

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

shugoshin 1

increases expression

Tacrolimus results in increased expression of SGO1 mRNA

NCBI chr 3:20,160,593...20,186,886
Ensembl chr 3:20,160,593...20,186,206

G

Src homology 2 domain containing F

decreases expression

Tacrolimus results in decreased expression of SHF mRNA

NCBI chr15:45,167,214...45,201,116
Ensembl chr15:45,167,214...45,201,175

G

Src like adaptor

increases expression

Tacrolimus results in increased expression of SLA mRNA

NCBI chr 8:133,036,728...133,102,602
Ensembl chr 8:133,036,728...133,102,912

G

solute carrier family 12 member 3

affects response to substance
decreases expression
increases phosphorylation

SLC12A3 protein affects the susceptibility to Tacrolimus
Tacrolimus results in decreased expression of SLC12A3 mRNA; Tacrolimus results in decreased expression of SLC12A3 protein
Tacrolimus results in increased phosphorylation of SLC12A3 protein

PMID:21865292 PMID:21963515

NCBI chr16:56,865,207...56,915,850
Ensembl chr16:56,865,207...56,915,850

G

solute carrier family 16 member 1

decreases expression

Tacrolimus results in decreased expression of SLC16A1 mRNA

NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,593

G

solute carrier family 22 member 13

decreases expression

Tacrolimus results in decreased expression of SLC22A13 mRNA

NCBI chr 3:38,265,812...38,278,757
Ensembl chr 3:38,265,812...38,278,757

G

solute carrier family 25 member 25

decreases expression

Tacrolimus results in decreased expression of SLC25A25 mRNA

NCBI chr 9:128,068,232...128,109,245
Ensembl chr 9:128,068,201...128,109,245

G

solute carrier family 34 member 2

increases expression

Tacrolimus results in increased expression of SLC34A2 mRNA

NCBI chr 4:25,655,851...25,678,748
Ensembl chr 4:25,648,011...25,678,748

G

SMAD family member 3

multiple interactions

Tacrolimus inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of SMAD3 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of SMAD3 mRNA]

NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173

G

SMAD family member 7

multiple interactions

Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]; Tacrolimus inhibits the reaction [SMAD7 protein binds to SMURF1 protein]
Tacrolimus promotes the reaction [Paraquat results in increased expression of and results in increased secretion of SMAD7 protein]; Tacrolimus promotes the reaction [Paraquat results in increased expression of SMAD7 mRNA]

PMID:16720724 PMID:33000210

NCBI chr18:48,919,853...48,950,965
Ensembl chr18:48,919,853...48,950,965

G

small integral membrane protein 14

increases expression

Tacrolimus results in increased expression of SMIM14 mRNA

NCBI chr 4:39,546,336...39,638,865
Ensembl chr 4:39,546,336...39,638,902

G

SMAD specific E3 ubiquitin protein ligase 1

multiple interactions

Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]; Tacrolimus inhibits the reaction [SMAD7 protein binds to SMURF1 protein]

NCBI chr 7:99,027,440...99,144,108
Ensembl chr 7:99,027,440...99,144,108

G

snail family transcriptional repressor 1

increases expression
multiple interactions

Tacrolimus results in increased expression of SNAI1 protein
[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]

NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886

G

snail family transcriptional repressor 2

increases expression

Tacrolimus results in increased expression of SNAI2 mRNA

NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740

G

small nucleolar RNA, H/ACA box 74D

increases expression

Tacrolimus results in increased expression of MIR1949 mRNA

NCBI chr 5:139,276,180...139,276,323
Ensembl chr 5:139,276,180...139,276,320

G

superoxide dismutase 2

increases response to substance
decreases expression
multiple interactions

SOD2 protein results in increased susceptibility to Tacrolimus
Tacrolimus results in decreased expression of SOD2 protein
MK0626 inhibits the reaction [Tacrolimus results in decreased expression of SOD2 protein]

PMID:14675044 PMID:24959755

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

SRY-box transcription factor 9

increases expression

Tacrolimus results in increased expression of SOX9 mRNA

NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416

G

Sp7 transcription factor

decreases expression

Tacrolimus results in decreased expression of SP7 mRNA

NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315

G

sperm acrosome associated 7

increases expression

Tacrolimus results in increased expression of SPACA7 mRNA

NCBI chr13:112,376,355...112,434,689
Ensembl chr13:112,376,355...112,434,689

G

signal peptidase complex subunit 2

increases expression

Tacrolimus results in increased expression of SPCS2 mRNA

NCBI chr11:74,949,266...74,979,033
Ensembl chr11:74,949,261...74,979,033

G

sphingosine kinase 2

decreases expression

Tacrolimus results in decreased expression of SPHK2 mRNA

NCBI chr19:48,619,506...48,630,405
Ensembl chr19:48,619,291...48,630,717

G

Spi-C transcription factor

increases expression

Tacrolimus results in increased expression of SPIC mRNA

NCBI chr12:101,475,336...101,486,997
Ensembl chr12:101,475,336...101,486,997

G

secreted phosphoprotein 1

increases expression

Tacrolimus results in increased expression of SPP1 mRNA

PMID:12472797 PMID:21865292

NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532

G

sulfide quinone oxidoreductase

decreases expression

Tacrolimus results in decreased expression of SQOR mRNA

NCBI chr15:45,631,148...45,691,281
Ensembl chr15:45,631,148...45,691,281

G

signal sequence receptor subunit 3

increases expression

Tacrolimus results in increased expression of SSR3 mRNA

NCBI chr 3:156,539,553...156,555,117
Ensembl chr 3:156,539,553...156,555,149

G

StAR related lipid transfer domain containing 4

decreases expression

Tacrolimus results in decreased expression of STARD4 mRNA

NCBI chr 5:111,496,033...111,512,535
Ensembl chr 5:111,496,033...111,512,590

G

signal transducer and activator of transcription 3

increases phosphorylation

Tacrolimus results in increased phosphorylation of STAT3 protein

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transcriptional adaptor 3

decreases expression

Tacrolimus results in decreased expression of TADA3 mRNA

NCBI chr 3:9,779,967...9,793,011
Ensembl chr 3:9,779,967...9,793,011

G

trafficking regulator and scaffold protein tamalin

increases expression

Tacrolimus results in increased expression of TAMALIN mRNA

NCBI chr12:52,006,946...52,015,889
Ensembl chr12:52,006,946...52,015,889

G

TatD DNase domain containing 1

increases expression

Tacrolimus results in increased expression of TATDN1 mRNA

NCBI chr 8:124,488,494...124,539,088
Ensembl chr 8:124,488,485...124,539,458

G

tektin 1

increases expression

Tacrolimus results in increased expression of TEKT1 mRNA

NCBI chr17:6,797,993...6,831,729
Ensembl chr17:6,789,133...6,831,761

G

transcription factor EB

multiple interactions

[Cyclosporine co-treated with Tacrolimus] inhibits the reaction [4-(4-fluorophenyl)sulfonyl-5-methylthio-2-phenyloxazole affects the localization of TFEB protein]

NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259

G

transferrin receptor

decreases expression

Tacrolimus results in decreased expression of TFRC protein

NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153

G

transforming growth factor beta 1

multiple interactions
increases expression
decreases expression

Ramipril inhibits the reaction [Tacrolimus results in increased expression of TGFB1 mRNA]
Tacrolimus results in increased expression of TGFB1 mRNA; Tacrolimus results in increased expression of TGFB1 protein
Tacrolimus results in decreased expression of TGFB1 mRNA
[Tacrolimus co-treated with Quinapril] results in increased expression of TGFB1 protein; [Tacrolimus co-treated with Valsartan] results in increased expression of TGFB1 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of TGFB1 mRNA]; Ramipril inhibits the reaction [Tacrolimus results in increased expression of TGFB1 protein]; Tacrolimus inhibits the reaction [Mercuric Chloride results in increased expression of TGFB1 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TGFB1 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]; Valsartan inhibits the reaction [Tacrolimus results in increased expression of TGFB1 protein]

PMID:9422427 PMID:11091246 PMID:12352326 PMID:12472797 PMID:14620542 More...

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transforming growth factor beta induced

increases expression

Tacrolimus results in increased expression of TGFBI mRNA

NCBI chr 5:136,028,988...136,063,818
Ensembl chr 5:136,028,988...136,063,818

G

transforming growth factor beta receptor 1

increases expression

Tacrolimus results in increased expression of TGFBR1 mRNA; Tacrolimus results in increased expression of TGFBR1 protein

NCBI chr 9:99,103,647...99,154,192
Ensembl chr 9:99,104,038...99,154,192

G

transforming growth factor beta receptor 2

increases expression

Tacrolimus results in increased expression of TGFBR2 mRNA; Tacrolimus results in increased expression of TGFBR2 protein

NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,601...30,694,142

G

transglutaminase 1

increases expression

Tacrolimus results in increased expression of TGM1 mRNA

NCBI chr14:24,249,114...24,263,177
Ensembl chr14:24,249,114...24,264,432

G

TIMP metallopeptidase inhibitor 1

multiple interactions
decreases expression
increases expression

pirfenidone promotes the reaction [Tacrolimus results in decreased expression of TIMP1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of TIMP1 mRNA]

PMID:11091246 PMID:12472797 PMID:15854665 PMID:21865292

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

toll like receptor 2

increases expression

Tacrolimus results in increased expression of TLR2 mRNA

NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260

G

transmembrane protein 202

decreases expression

Tacrolimus results in decreased expression of TMEM202 mRNA

NCBI chr15:72,398,305...72,408,367
Ensembl chr15:72,398,302...72,408,367

G

tumor necrosis factor

multiple interactions
increases expression
decreases expression
decreases secretion

Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF protein]; Tacrolimus inhibits the reaction [Dieldrin results in increased expression of TNF mRNA]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of TNF protein]; Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Tacrolimus inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Tacrolimus results in increased expression of TNF mRNA
Tacrolimus inhibits the reaction [Indomethacin results in increased expression of TNF mRNA]
[Tacrolimus co-treated with Thapsigargin] results in increased expression of TNF protein
Tacrolimus results in decreased expression of TNF mRNA; Tacrolimus results in decreased expression of TNF protein
Tacrolimus results in decreased secretion of TNF protein

PMID:1371491 PMID:10339586 PMID:10385251 PMID:10685002 PMID:11121130 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF alpha induced protein 8 like 2

increases expression

Tacrolimus results in increased expression of TNFAIP8L2 mRNA

NCBI chr 1:151,156,649...151,159,749
Ensembl chr 1:151,156,649...151,159,749

G

TNF receptor superfamily member 11b

decreases expression

Tacrolimus results in decreased expression of TNFRSF11B mRNA

NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885

G

TNF superfamily member 11

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]

PMID:15207740 PMID:21869564

NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013

G

troponin T2, cardiac type

increases expression

Tacrolimus results in increased expression of TNNT2 protein

NCBI chr 1:201,359,014...201,377,680
Ensembl chr 1:201,359,008...201,377,764

G

tumor protein p53

multiple interactions

Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TRP53 protein]

PMID:10205001 PMID:12642403

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

tribbles pseudokinase 3

increases expression

Tacrolimus results in increased expression of TRIB3 mRNA

NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559

G

tripartite motif containing 2

decreases expression

Tacrolimus results in decreased expression of TRIM2 mRNA

NCBI chr 4:153,152,163...153,339,317
Ensembl chr 4:153,152,163...153,339,319

G

thyroid hormone receptor interactor 13

increases expression

Tacrolimus results in increased expression of TRIP13 mRNA

NCBI chr 5:892,884...919,348
Ensembl chr 5:892,884...919,357

G

transient receptor potential cation channel subfamily M member 6

decreases expression

Tacrolimus results in decreased expression of TRPM6 mRNA

NCBI chr 9:74,722,495...74,887,921
Ensembl chr 9:74,722,495...74,888,094

G

transient receptor potential cation channel subfamily V member 1

multiple interactions

Tacrolimus results in increased phosphorylation of and affects the activity of TRPV1 protein
Tacrolimus affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

transient receptor potential cation channel subfamily V member 5

decreases expression

Tacrolimus results in decreased expression of TRPV5 mRNA; Tacrolimus results in decreased expression of TRPV5 protein

NCBI chr 7:142,908,101...142,933,746
Ensembl chr 7:142,908,101...142,933,746

G

thioredoxin

decreases expression

Tacrolimus results in decreased expression of TXN mRNA

NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507

G

ubiquitin D

increases expression

Tacrolimus results in increased expression of UBD mRNA

NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732

G

undifferentiated embryonic cell transcription factor 1

decreases expression

Tacrolimus results in decreased expression of UTF1 mRNA

NCBI chr10:133,230,217...133,231,558
Ensembl chr10:133,230,217...133,231,558

G

vasorin

decreases expression

Tacrolimus results in decreased expression of VASN mRNA

NCBI chr16:4,371,848...4,383,538
Ensembl chr16:4,371,848...4,383,538

G

vasodilator stimulated phosphoprotein

decreases expression

Tacrolimus results in decreased expression of VASP mRNA

NCBI chr19:45,507,479...45,526,983
Ensembl chr19:45,506,579...45,526,989

G

vascular cell adhesion molecule 1

increases expression

Tacrolimus results in increased expression of VCAM1 mRNA

PMID:23958496 PMID:29362864

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

versican

increases expression

Tacrolimus results in increased expression of VCAN mRNA

NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303

G

vascular endothelial growth factor A

increases expression

Tacrolimus results in increased expression of VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vimentin

increases expression

Tacrolimus results in increased expression of VIM protein

PMID:22416070 PMID:29362864

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

WDFY family member 4

increases expression

Tacrolimus results in increased expression of WDFY4 mRNA

NCBI chr10:48,684,873...48,982,956
Ensembl chr10:48,684,873...48,982,956

G

WD repeat domain 31

decreases expression

Tacrolimus results in decreased expression of WDR31 mRNA

NCBI chr 9:113,313,222...113,340,275
Ensembl chr 9:113,313,222...113,340,298

G

WD repeat domain 54

decreases expression

Tacrolimus results in decreased expression of WDR54 mRNA

NCBI chr 2:74,421,730...74,425,755
Ensembl chr 2:74,421,678...74,425,755

G

WD repeat domain 73

decreases expression

Tacrolimus results in decreased expression of WDR73 mRNA

NCBI chr15:84,639,285...84,654,283
Ensembl chr15:84,639,285...84,654,343

G

WNK lysine deficient protein kinase 3

increases phosphorylation

Tacrolimus results in increased phosphorylation of WNK3 protein

NCBI chr X:54,192,823...54,358,900
Ensembl chr X:54,192,823...54,358,642

G

WNK lysine deficient protein kinase 4

increases phosphorylation

Tacrolimus results in increased phosphorylation of WNK4 protein

NCBI chr17:42,780,610...42,797,066
Ensembl chr17:42,780,610...42,797,066

G

X-box binding protein 1

multiple interactions
increases expression

Tacrolimus results in increased expression of and affects the localization of XBP1 protein modified form
Tacrolimus results in increased expression of XBP1 mRNA

PMID:23958496 PMID:25270620

NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597

G

X-C motif chemokine ligand 1

increases expression

Tacrolimus results in increased expression of XCL1 mRNA

NCBI chr 1:168,576,605...168,582,069
Ensembl chr 1:168,576,605...168,582,069

G

zinc finger FYVE-type containing 16

increases expression

Tacrolimus results in increased expression of ZFYVE16 mRNA

NCBI chr 5:80,407,610...80,483,379
Ensembl chr 5:80,408,013...80,483,379

G

zinc finger protein 785

increases expression
decreases expression

Tacrolimus results in increased expression of ZFP459 mRNA
Tacrolimus results in decreased expression of ZFP459 mRNA

PMID:21621594 PMID:29362864

NCBI chr16:30,578,361...30,585,697
Ensembl chr16:30,573,740...30,585,769

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26034
role	25961
chemical role	24242
greenhouse gas	13482
water	753
hydrate	720
(+)-catechin monohydrate	0
(R)-DRF053 hydrochloride hydrate	0
(R)-tosufloxacin tosylate hydrate +	0
(S)-ropivacaine hydrochloride hydrate	0
(S)-timolol hemihydrate	0
(S)-tosufloxacin tosylate hydrate +	0
1-O-alpha-D-glucopyranosyl-D-mannitol dihydrate +	0
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride hydrate +	0
EDTA disodium salt dihydrate	0
L-cysteine hydrochloride hydrate	0
L-dehydroascorbic acid hydrate	0
alendronate sodium trihydrate	0
aluminium sulfate hexadecahydrate	0
aluminium sulfate octadecahydrate	0
aluminium trichloride hexahydrate	0
amfenac sodium hydrate	0
amidotrizoic acid dihydrate	0
amiloride hydrochloride dihydrate	0
ammonium magnesium phosphate hexahydrate	0
ammonium magnesium phosphate monohydrate	0
ammonium nickel sulfate hexahydrate	0
amoxicillin trihydrate +	25
ampicillin trihydrate	0
apomorphine hydrochloride	0
atorvastatin calcium trihydrate	0
azithromycin dihydrate	0
balsalazide disodium	0
barium chloride dihydrate	0
bepridil hydrochloride monohydrate	0
beryllium sulfate tetrahydrate	0
borax	0
bosentan hydrate	0
bosutinib hydrate	0
bromfenac sodium salt sesquihydrate	0
bumadizone calcium hemihydrate	0
cadmium dichloride hemipentahydrate	0
cadmium nitrate tetrahydrate	0
cadmium sulfate hydrate	0
caffeine monohydrate	0
calcipotriol hydrate +	0
calcium acetate monohydrate	0
calcium chloride dihydrate	0
calcium chloride hexahydrate	0
calcium hydrogenphosphate dihydrate	0
calcium nitrate tetrahydrate	0
calcium sulfate dihydrate +	0
calcium sulfate hemihydrate	0
canagliflozin hydrate	0
carbidopa	19
cefadroxil monohydrate	0
cefepime hydrochloride	0
ceftaroline fosamil acetate monohydrate	0
ceftazidime pentahydrate +	4
ceftibuten dihydrate	0
cephalexin monohydrate	0
cetylpyridinium chloride monohydrate	0
chromium trinitrate heptahydrate	0
chromium(3+) trichloride hexahydrate	0
cidofovir dihydrate	0
cilazapril monohydrate	10
ciprofloxacin hydrochloride hydrate	0
cloxacillin sodium monohydrate	0
cobalt chloride hexahydrate	0
cobalt dinitrate hexahydrate	0
cobalt(2+) sulfate heptahydrate	0
copper(II) chloride dihydrate	0
copper(II) chloride pentahydrate	0
copper(II) sulfate hexahydrate	0
copper(II) sulfate pentahydrate	0
cyclophosphamide hydrate	0
cyproheptadine hydrochloride sesquihydrate	0
dantrolene sodium hemiheptahydrate	0
dapagliflozin propanediol monohydrate	0
dasabuvir sodium hydrate +	0
dasatinib monohydrate	0
desmopressin acetate trihydrate	0
dextromethorphan hydrobromide	0
dextropropoxyphene napsylate	0
dicloxacillin sodium monohydrate	0
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate	210
disodium clodronate tetrahydrate	0
disodium hydrogenarsenate heptahydrate	0
disodium hydrogenphosphate dihydrate	0
disodium hydrogenphosphate dodecahydrate	0
disodium perborate hexahydrate	0
disodium selenite pentahydrate	0
disodium tetraborate decahydrate	0
disodium tetraborate octahydrate	0
docetaxel trihydrate	0
doxapram hydrochloride monohydrate	0
doxycycline hyclate	0
doxycycline monohydrate	0
edoxaban tosylate hydrate	0
eflornithine hydrochloride monohydrate	0
emetine dihydrochloride hydrate	0
enalaprilat dihydrate	22
entecavir hydrate	0
esculin hydrate	0
fasudil hydrochloride hydrate	0
fenoprofen calcium	0
ferrous ammonium sulfate heptahydrate	0
ferrous ammonium sulfate hexahydrate	0
flucloxacillin sodium monohydrate	0
gadodiamide hydrate	51
glycine betaine hydrate	0
hexaammonium heptamolybdate tetrahydrate	0
hydrazine hydrate	0
ipratropium bromide hydrate	0
iptacopan hydrochloride monohydrate	0
irinotecan hydrochloride hydrate	0
iron dichloride tetrahydrate	0
iron trichloride hexahydrate	0
iron(2+) sulfate heptahydrate	0
iron(2+) sulfate monohydrate	0
iron(3+) phosphate tetrahydrate	0
iron(3+) sulfate hydrate	0
iron(III) citrate monohydrate	0
lead diacetate trihydrate	0
levopropoxyphene napsylate	0
lidocaine hydrochloride monohydrate	0
lisinopril dihydrate	20
lithium citrate tetrahydrate	0
lorcaserin hydrochloride hemihydrate	0
loxoprofen sodium hydrate	0
magnesium dichloride dihydrate	0
magnesium dichloride hexahydrate	0
magnesium dichloride monohydrate	0
magnesium formate dihydrate	0
magnesium sulfate heptahydrate	0
manganese(II) chloride dihydrate	0
manganese(II) chloride tetrahydrate	0
manganese(II) sulfate dihydrate	0
manganese(II) sulfate hexahydrate	0
manganese(II) sulfate monohydrate	0
manganese(II) sulfate pentahydrate	0
manganese(II) sulfate tetrahydrate	0
mercaptopurine hydrate	0
meropenem trihydrate	0
methicillin sodium monohydrate	0
methixene hydrochloride	0
metoclopramide dihydrochloride monohydrate	0
metoclopramide hydrochloride +	0
mezlocillin sodium monohydrate	0
mitoguazone hydrochloride hydrate	0
morphine hydrochloride trihydrate	0
morphine sulfate pentahydrate	0
mosapride citrate dihydrate	6
mupirocin calcium hydrate	0
nafarelin acetate hydrate	0
nafcillin sodium monohydrate	0
nickel chloride hexahydrate	0
nickel sulfate heptahydrate	0
nickel sulfate hexahydrate	0
oxacillin sodium monohydrate	0
oxyphenbutazone hydrate	0
pemetrexed disodium heptahydrate	0
peramivir hydrate +	0
perampanel hydrate	0
potassium aluminium sulfate dodecahydrate	0
potassium citrate monohydrate	1
pramipexole hydrochloride	0
quinine sulfate dihydrate	0
regorafenib hydrate	0
rolapitant hydrochloride hydrate	0
saxagliptin hydrate	0
scopolamine hydrobromide trihydrate	0
sodium acetate trihydrate	30
sodium citrate dihydrate	0
sodium dihydrogenphosphate monohydrate	0
sodium glycerol 2-phosphate tetrahydrate	0
sodium meclofenamate monohydrate	0
sodium metavanadate dihydrate	0
sodium metavanadate hydrate	0
sodium molybdate dihydrate	0
sodium molybdate heptahydrate	0
sodium molybdate tetrahydrate	0
sodium nitroprusside dihydrate	0
sodium pyrophosphate decahydrate	0
sodium silicate nonahydrate	0
sodium succinate hexahydrate	0
sodium sulfate decahydrate	0
sodium sulfide nonahydrate	0
sodium thiosulfate pentahydrate	3
sodium tungstate dihydrate	0
spectinomycin hydrochloride hydrate	0
strontium dichloride hexahydrate	0
succinylcholine chloride dihydrate	0
sulfacetamide sodium	0
tacrolimus hydrate	436
taltirelin tetrahydrate	0
tenofovir hydrate	0
terazosin hydrochloride dihydrate	0
tetrahydroxy-1,4-benzoquinone hydrate	0
thiamine hydrochloride dihydrate	0
tin(II) chloride dihydrate	0
tiotropium bromide hydrate +	0
tolmetin sodium dihydrate	0
triprolidine hydrochloride monohydrate	0
tris(1,10-phenanthroline)ruthenium(II) dichloride dihydrate	0
trisodium phosphate decahydrate	0
trisodium phosphonoformate hexahydrate	0
vanadyl sulfate hydrate +	0
zinc sulfate heptahydrate	0
zinc sulfate hexahydrate	0
ziprasidone hydrochloride hydrate	0
ziprasidone mesylate trihydrate	0
Path 2
Term	Annotations
CHEBI ontology	26034
subatomic particle	26009
composite particle	26009
hadron	26020
baryon	26009
nucleon	26009
atomic nucleus	26009
atom	26009
main group element atom	25834
main group molecular entity	25834
s-block molecular entity	25166
hydrogen molecular entity	24765
hydrides	22965
inorganic hydride	20483
chalcogen hydride	2654
oxygen hydride	871
water	753
hydrate	720
(+)-catechin monohydrate	0
(R)-DRF053 hydrochloride hydrate	0
(R)-tosufloxacin tosylate hydrate +	0
(S)-ropivacaine hydrochloride hydrate	0
(S)-timolol hemihydrate	0
(S)-tosufloxacin tosylate hydrate +	0
1-O-alpha-D-glucopyranosyl-D-mannitol dihydrate +	0
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride hydrate +	0
EDTA disodium salt dihydrate	0
L-cysteine hydrochloride hydrate	0
L-dehydroascorbic acid hydrate	0
alendronate sodium trihydrate	0
aluminium sulfate hexadecahydrate	0
aluminium sulfate octadecahydrate	0
aluminium trichloride hexahydrate	0
amfenac sodium hydrate	0
amidotrizoic acid dihydrate	0
amiloride hydrochloride dihydrate	0
ammonium magnesium phosphate hexahydrate	0
ammonium magnesium phosphate monohydrate	0
ammonium nickel sulfate hexahydrate	0
amoxicillin trihydrate +	25
ampicillin trihydrate	0
apomorphine hydrochloride	0
atorvastatin calcium trihydrate	0
azithromycin dihydrate	0
balsalazide disodium	0
barium chloride dihydrate	0
bepridil hydrochloride monohydrate	0
beryllium sulfate tetrahydrate	0
borax	0
bosentan hydrate	0
bosutinib hydrate	0
bromfenac sodium salt sesquihydrate	0
bumadizone calcium hemihydrate	0
cadmium dichloride hemipentahydrate	0
cadmium nitrate tetrahydrate	0
cadmium sulfate hydrate	0
caffeine monohydrate	0
calcipotriol hydrate +	0
calcium acetate monohydrate	0
calcium chloride dihydrate	0
calcium chloride hexahydrate	0
calcium hydrogenphosphate dihydrate	0
calcium nitrate tetrahydrate	0
calcium sulfate dihydrate +	0
calcium sulfate hemihydrate	0
canagliflozin hydrate	0
carbidopa	19
cefadroxil monohydrate	0
cefepime hydrochloride	0
ceftaroline fosamil acetate monohydrate	0
ceftazidime pentahydrate +	4
ceftibuten dihydrate	0
cephalexin monohydrate	0
cetylpyridinium chloride monohydrate	0
chromium trinitrate heptahydrate	0
chromium(3+) trichloride hexahydrate	0
cidofovir dihydrate	0
cilazapril monohydrate	10
ciprofloxacin hydrochloride hydrate	0
cloxacillin sodium monohydrate	0
cobalt chloride hexahydrate	0
cobalt dinitrate hexahydrate	0
cobalt(2+) sulfate heptahydrate	0
copper(II) chloride dihydrate	0
copper(II) chloride pentahydrate	0
copper(II) sulfate hexahydrate	0
copper(II) sulfate pentahydrate	0
cyclophosphamide hydrate	0
cyproheptadine hydrochloride sesquihydrate	0
dantrolene sodium hemiheptahydrate	0
dapagliflozin propanediol monohydrate	0
dasabuvir sodium hydrate +	0
dasatinib monohydrate	0
desmopressin acetate trihydrate	0
dextromethorphan hydrobromide	0
dextropropoxyphene napsylate	0
dicloxacillin sodium monohydrate	0
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate	210
disodium clodronate tetrahydrate	0
disodium hydrogenarsenate heptahydrate	0
disodium hydrogenphosphate dihydrate	0
disodium hydrogenphosphate dodecahydrate	0
disodium perborate hexahydrate	0
disodium selenite pentahydrate	0
disodium tetraborate decahydrate	0
disodium tetraborate octahydrate	0
docetaxel trihydrate	0
doxapram hydrochloride monohydrate	0
doxycycline hyclate	0
doxycycline monohydrate	0
edoxaban tosylate hydrate	0
eflornithine hydrochloride monohydrate	0
emetine dihydrochloride hydrate	0
enalaprilat dihydrate	22
entecavir hydrate	0
esculin hydrate	0
fasudil hydrochloride hydrate	0
fenoprofen calcium	0
ferrous ammonium sulfate heptahydrate	0
ferrous ammonium sulfate hexahydrate	0
flucloxacillin sodium monohydrate	0
gadodiamide hydrate	51
glycine betaine hydrate	0
hexaammonium heptamolybdate tetrahydrate	0
hydrazine hydrate	0
ipratropium bromide hydrate	0
iptacopan hydrochloride monohydrate	0
irinotecan hydrochloride hydrate	0
iron dichloride tetrahydrate	0
iron trichloride hexahydrate	0
iron(2+) sulfate heptahydrate	0
iron(2+) sulfate monohydrate	0
iron(3+) phosphate tetrahydrate	0
iron(3+) sulfate hydrate	0
iron(III) citrate monohydrate	0
lead diacetate trihydrate	0
levopropoxyphene napsylate	0
lidocaine hydrochloride monohydrate	0
lisinopril dihydrate	20
lithium citrate tetrahydrate	0
lorcaserin hydrochloride hemihydrate	0
loxoprofen sodium hydrate	0
magnesium dichloride dihydrate	0
magnesium dichloride hexahydrate	0
magnesium dichloride monohydrate	0
magnesium formate dihydrate	0
magnesium sulfate heptahydrate	0
manganese(II) chloride dihydrate	0
manganese(II) chloride tetrahydrate	0
manganese(II) sulfate dihydrate	0
manganese(II) sulfate hexahydrate	0
manganese(II) sulfate monohydrate	0
manganese(II) sulfate pentahydrate	0
manganese(II) sulfate tetrahydrate	0
mercaptopurine hydrate	0
meropenem trihydrate	0
methicillin sodium monohydrate	0
methixene hydrochloride	0
metoclopramide dihydrochloride monohydrate	0
metoclopramide hydrochloride +	0
mezlocillin sodium monohydrate	0
mitoguazone hydrochloride hydrate	0
morphine hydrochloride trihydrate	0
morphine sulfate pentahydrate	0
mosapride citrate dihydrate	6
mupirocin calcium hydrate	0
nafarelin acetate hydrate	0
nafcillin sodium monohydrate	0
nickel chloride hexahydrate	0
nickel sulfate heptahydrate	0
nickel sulfate hexahydrate	0
oxacillin sodium monohydrate	0
oxyphenbutazone hydrate	0
pemetrexed disodium heptahydrate	0
peramivir hydrate +	0
perampanel hydrate	0
potassium aluminium sulfate dodecahydrate	0
potassium citrate monohydrate	1
pramipexole hydrochloride	0
quinine sulfate dihydrate	0
regorafenib hydrate	0
rolapitant hydrochloride hydrate	0
saxagliptin hydrate	0
scopolamine hydrobromide trihydrate	0
sodium acetate trihydrate	30
sodium citrate dihydrate	0
sodium dihydrogenphosphate monohydrate	0
sodium glycerol 2-phosphate tetrahydrate	0
sodium meclofenamate monohydrate	0
sodium metavanadate dihydrate	0
sodium metavanadate hydrate	0
sodium molybdate dihydrate	0
sodium molybdate heptahydrate	0
sodium molybdate tetrahydrate	0
sodium nitroprusside dihydrate	0
sodium pyrophosphate decahydrate	0
sodium silicate nonahydrate	0
sodium succinate hexahydrate	0
sodium sulfate decahydrate	0
sodium sulfide nonahydrate	0
sodium thiosulfate pentahydrate	3
sodium tungstate dihydrate	0
spectinomycin hydrochloride hydrate	0
strontium dichloride hexahydrate	0
succinylcholine chloride dihydrate	0
sulfacetamide sodium	0
tacrolimus hydrate	436
taltirelin tetrahydrate	0
tenofovir hydrate	0
terazosin hydrochloride dihydrate	0
tetrahydroxy-1,4-benzoquinone hydrate	0
thiamine hydrochloride dihydrate	0
tin(II) chloride dihydrate	0
tiotropium bromide hydrate +	0
tolmetin sodium dihydrate	0
triprolidine hydrochloride monohydrate	0
tris(1,10-phenanthroline)ruthenium(II) dichloride dihydrate	0
trisodium phosphate decahydrate	0
trisodium phosphonoformate hexahydrate	0
vanadyl sulfate hydrate +	0
zinc sulfate heptahydrate	0
zinc sulfate hexahydrate	0
ziprasidone hydrochloride hydrate	0
ziprasidone mesylate trihydrate	0

paths to the root